06 July 2023
EMA/CHMP/217936/2023
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 24-26 April 2023

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Disclaimers

Some of the information contained in set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, the minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. The meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the list of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CHMP agenda for 24-26 April 2023.

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 27-30 March 2023.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 17 April 2023.

The CHMP adopted the CHMP minutes for 27-30 March 2023.

The CHMP adopted the minutes from the PROM meeting held on 17 April 2023.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. aripiprazole - EMEA/H/C/005929

Maintenance treatment of schizophrenia

Scope: Oral explanation

Action: Oral explanation to be held on 25 April 2023 at 14:00

List of Outstanding Issues adopted on 26.01.2023. List of Questions adopted on 13.10.2022.

An oral explanation was held on 25 April 2023. The presentation by the applicant focused on regulatory aspects in support of the application.

2.1.2. gadopiclenol - EMEA/H/C/005626

for diagnostic: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate).

Scope: Possible oral explanation

Action: Oral explanation to be held on 25 April 2023 at 11:00

List of Outstanding Issues adopted on 10.11.2022. List of Questions adopted on 23.06.2022.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.1.3. gadopiclenol - EMEA/H/C/006172

for diagnostic: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate).

Scope: Possible oral explanation

Action: Oral explanation to be held on 25 April 2023 at 11:00

List of Outstanding Issues adopted on 10.11.2022.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. Opdivo - nivolumab - EMEA/H/C/003985/II/0117

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include Opdivo in combination with platinum-based

chemotherapy for neoadjuvant treatment of adult patients with resectable stage IB-IIIA non-small cell lung cancer (NSCLC), based on results from study CA209816; a randomised, open-label, phase 3 trial of nivolumab plus ipilimumab or nivolumab plus platinum-doublet chemotherapy versus platinum-doublet chemotherapy in early-stage NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 27.0 of the RMP has also been submitted."

Scope: Oral explanation

Action: Oral explanation to be held on 24 April 2023 at 14:00

Request for Supplementary Information adopted on 23.02.2023, 13.10.2022, 23.06.2022.

An oral explanation was held on 24 April 2023. The presentation by the applicant focused on the clinical data in support of the application.

See 5.1

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Arexvy - recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E - EMEA/H/C/006054

GlaxoSmithkline Biologicals S.A.; indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by RSV

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 28.03.2023. List of Questions adopted on 24.01.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considers that Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation (RSVPreF3) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 21 April 2023.

The summary of opinion was circulated for information.

3.1.2. Camzyos - mavacamten - EMEA/H/C/005457

Bristol-Myers Squibb Pharma EEIG; treatment of symptomatic obstructive hypertrophic cardiomyopathy

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.02.2023, 15.12.2022, 21.07.2022. List of Questions adopted on 27.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that mavacamten is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 21 April 2023.

The summary of opinion was circulated for information.

3.1.3. Columvi - glofitamab - Orphan - EMEA/H/C/005751

Roche Registration GmbH; treatment of diffuse large B-cell lymphoma

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.02.2023. List of Questions adopted on 15.09.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that glofitamab is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.4. Jaypirca - pirtobrutinib - Orphan - EMEA/H/C/005863

Eli Lilly Nederland B.V.; treatment of mantle cell lymphoma (MCL)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.02.2023. List of Questions adopted on 13.10.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that pirtobrutinib is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.5. Lytgobi - futibatinib - Orphan - EMEA/H/C/005627

Taiho Pharma Netherlands B.V.; treatment of cholangiocarcinoma

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.02.2023. List of Questions adopted on 15.09.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by majority (26 out of 28 votes) recommending the granting of a conditional marketing authorisation together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that futibatinib is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The divergent position (Martina Weise and Armando Genazzani) was appended to the opinion.

The CHMP noted the letter of recommendation dated 26 April 2023.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.6. Opfolda - miglustat - EMEA/H/C/005695

Amicus Therapeutics Europe Limited; treatment of adults aged 18 years and older with a confirmed diagnosis of Pompe disease

Scope: Opinion

Action: For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 10.11.2022, 15.09.2022. List of Questions adopted on 24.03.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 20 April 2023.

The summary of opinion was circulated for information.

3.1.7. Sugammadex Piramal - sugammadex - EMEA/H/C/006083

Piramal Critical Care B.V.; Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Bridion

List of Outstanding Issues adopted on 30.03.2023. List of Questions adopted on 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. degarelix acetate - EMEA/H/C/006048

treatment of prostate cancer

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 10.11.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. gadopiclenol - EMEA/H/C/005626

for diagnostic: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate).

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 10.11.2022. List of Questions adopted on 23.06.2022.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP agreed that an oral explanation was not needed at this time.

The Committee adopted a 2nd list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of outstanding issues.

3.2.3. gefapixant - EMEA/H/C/005884

treatment of refractory or unexplained chronic cough

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022, 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 4th list of outstanding issues with a specific timetable.

3.2.4. pegfilgrastim - EMEA/H/C/005587

treatment of neutropenia

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

The CHMP did not agree to the request by the applicant for an extension of clock-stop to respond to the list of outstanding issues but agreed to a shorter clock stop extension.

3.2.5. gefapixant - EMEA/H/C/005476

treatment of refractory or unexplained chronic cough

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022, 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 4th list of outstanding issues with a specific timetable.

3.2.6. natalizumab - EMEA/H/C/005752

Therapy for active relapsing remitting multiple sclerosis (RRMS)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 10.11.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.7. gadopiclenol - EMEA/H/C/006172

for diagnostic: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate).

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 10.11.2022.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP agreed that an oral explanation was not needed at this time.

The Committee adopted a 2nd list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of outstanding issues.

3.2.8. ganaxolone - Orphan - EMEA/H/C/005825

Marinus Pharmaceuticals Emerald Limited; treatment of epileptic seizures associated with cyclindependent kinase-like 5 deficiency disorder (CDD)

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 26.01.2023. List of Questions adopted on 25.01.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. respiratory syncytial virus vaccines - EMEA/H/C/006027

Accelerated assessment

prevention of respiratory tract disease

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. azacitidine - EMEA/H/C/006154

Treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) - EMEA/H/C/006052

Active immunisation for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. germanium (68ge) chloride / gallium (68ga) chloride - EMEA/H/C/006053

indicated for in vitro radiolabelling of specific carrier molecules to be used for positron emission tomography (PET) imaging

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.5. Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) - EMEA/H/C/006051

Prophylaxis of influenza

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. omecamtiv mecarbil - EMEA/H/C/006112

treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction less than 30%

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with

the list of questions.

3.3.7. bevacizumab - EMEA/H/C/005723

Treatment of neovascular (wet) age-related macular degeneration (nAMD).

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.8. nintedanib - EMEA/H/C/006179

treatment of idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung diseases (ILDs) and lung diseases (ILDs) systemic sclerosis associated interstitial lung disease (SSc-ILD)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.9. omaveloxolone - Orphan - EMEA/H/C/006084

Reata Ireland Limited; Treatment of Friedreich's ataxia

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.10. talquetamab - PRIME - Orphan - EMEA/H/C/005864

Accelerated assessment

Janssen-Cilag International N.V.; monotherapy treatment of adult patients with relapsed and refractory multiple myeloma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

No items

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Sohonos - palovarotene - Orphan - EMEA/H/C/004867

Ipsen Pharma; treatment of fibrodysplasia ossificans progressiva

Scope: List of questions for an ad-hoc expert group; draft list of experts for the AHEG

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 26.01.2023. List of Outstanding Issues adopted on 15.09.2022. List of Questions adopted on 16.09.2021.

The CHMP adopted the list of questions for an ad-hoc expert group.

3.5.2. Lagevrio - molnupiravir - EMEA/H/C/005789

Merck Sharp & Dohme B.V.; treatment of coronavirus disease 2019 (COVID-19)

Scope: Re-examination timetable

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 23.02.2023. List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 24.02.2022, 16.12.2021.

The CHMP adopted the re-examination timetable.

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. Tidhesco - ivosidenib - Orphan - EMEA/H/C/006174

Les Laboratoires Servier; treatment of acute myeloid leukaemia

Scope: Withdrawal of marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC), Duplicate of Tibsovo

Opinion adopted on 23.02.2023. List of Outstanding Issues adopted on 15.12.2022. List of Questions adopted on 21.07.2022.

The CHMP noted the withdrawal of the marketing authorisation application.

3.7.2. Lumevoq - lenadogene nolparvovec - Orphan - ATMP - EMEA/H/C/005047

GenSight Biologics S.A.; treatment of vision loss due to Leber Hereditary Optic Neuropathy (LHON)

Scope: Withdrawal of marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 09.12.2022. List of Questions adopted on 19.02.2021.

The CHMP noted the withdrawal of the marketing authorisation application.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Orkambi - lumacaftor / ivacaftor - EMEA/H/C/003954/X/0078/G

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Armando Genazzani, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension of indication to include treatment of cystic fibrosis for children aged 1 to less than 2 years of age who are homozygous for the F508del mutation in the CFTR gene, based on final results from study 122, a 2-part study of CF subjects 1 to <2 years of age homozygous for F508del. As a consequence, sections 4.1, 4.2, 4.5, 4.6, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Annex II has also been updated. In addition, the MAH took the opportunity to implement minor updates in the Product Information. Version 11.4 of the RMP has also been approved."

Action: For adoption

List of Outstanding Issues adopted on 23.02.2023. List of Questions adopted on 13.10.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP noted the letter of recommendation dated 24 April 2023.

The CHMP adopted the similarity assessment report.

The summary of opinion was circulated for information.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Tenkasi - oritavancin - EMEA/H/C/003785/X/0036

Menarini International Operations Luxembourg S.A.

Rapporteur: Janet Koenig, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension application to add a new strength of 1200 mg powder for concentrate for solution for infusion. The RMP (version 4) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 23.02.2023. List of Questions adopted on 21.07.2022.

The Committee discussed the issues identified in this application, relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the 2nd list of outstanding issues.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Azacitidine Accord - azacitidine - EMEA/H/C/005147/X/0013

Accord Healthcare S.L.U.

Rapporteur: Hrefna Gudmundsdottir, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (10 mg/ml powder for solution for infusion) and a new route of administration (intravenous use). The RMP version 2 is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, relating to quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.2. Entyvio - vedolizumab - EMEA/H/C/002782/X/0075

Takeda Pharma A/S

Rapporteur: Armando Genazzani

Scope: quality variation

Action: For adoption

The Committee discussed the issues identified in this application, relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with

the list of questions.

4.3.3. Kaftrio - ivacaftor / tezacaftor / elexacaftor - Orphan - EMEA/H/C/005269/X/0033

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber

Scope: "Extension application to add a new pharmaceutical form (granules) associated with 2 new strengths (60 mg/40 mg/80 mg and 75 mg/50 mg/100 mg) to support a new indication in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the CFTR gene. The new indication is only applicable to the new granules pharmaceutical form. As a consequence of the line extension, the PI for the film coated tablets is also updated to reflect the addition of a new pharmaceutical form.
The RMP (version 6.2) has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to quality and clinical aspects as well as the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.4. Kalydeco - ivacaftor - EMEA/H/C/002494/X/0114/G

Vertex Pharmaceuticals (Ireland) Limited

Co-Rapporteur: Beata Maria Jakline Ullrich, PRAC Rapporteur: Monica Martinez Redondo

Scope: "Extension application to add a new strength (59.5 mg) of the granules pharmaceutical form grouped with C.I.6.a, to support a new indication in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the CFTR gene (see section 5.1). The RMP (version 15.1) has also been submitted.
Type IB B.II.f.1.b
The Product information has been updated accordingly."

Action: For adoption

The Committee discussed the issues identified in this application, relating to quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Adempas - riociguat - EMEA/H/C/002737/II/0037

Bayer AG

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to add the treatment of PAH in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class (FC) II to III in combination with endothelin receptor antagonists for Adempas, based on results from pivotal study PATENT-CHILD (Study 15681); this is a Phase III, Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with PAH; As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.4 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.
The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

5.1.2. Ayvakit - avapritinib - Orphan - EMEA/H/C/005208/II/0023

Blueprint Medicines (Netherlands) B.V.

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of adult patients with indolent systemic mastocytosis (ISM) for avapritinib based on results from the pivotal part of study BLU-285-2203 (PIONEER), this is a 3-part, randomized, double-blind, placebo-controlled, Phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285) in indolent and smoldering systemic mastocytosis with symptoms inadequately controlled with standard therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.3. Bimzelx - bimekizumab - EMEA/H/C/005316/II/0010

UCB Pharma S.A.

Rapporteur: Finbarr Leacy, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension of indication to include treatment of adults with active axial spondyloarthritis (axSpA), including non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS, radiographic axial spondyloarthritis), based on interim results from two interventional and controlled phase III clinical studies: AS0010 (BE MOBILE 1) and AS0011 (BE MOBILE 2), which provide evidence of the efficacy and safety of bimekizumab in axSpA (nr-axSpA and AS), both compared to placebo treatment. Further supportive data is provided by the results of a phase 2a exploratory study (AS0013), a phase 2b, dose-ranging study (AS0008) and its ongoing follow-on phase 2b open-label extension (OLE) study (AS0009). As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.2 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.2 rev.1."

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023, 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.4. Bimzelx - bimekizumab - EMEA/H/C/005316/II/0011

UCB Pharma S.A.

Rapporteur: Finbarr Leacy, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension of indication to include treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to one or more

DMARDs for BIMZELX, based on interim results of a Phase III study in biological DMARD naïve study participants (PA0010; BE OPTIMAL) and the final results of the Phase III study in study participants who are inadequate responders (inadequate response or intolerant) to ≤2 prior TNF inhibitors (PA0011; BE COMPLETE). Both Phase III studies are interventional studies aimed to evaluate the efficacy and safety of bimekizumab. For PA0010, the Initial Treatment Period was placebo- and no inferential active reference (adalimumab)-controlled, while PA0011 was placebo-controlled. Further supportive data comprise the results of a Phase 1 study (PA0007), a Phase 2b dose-finding study (PA0008) and a Phase 2 open label extension study (PA0009). A Phase 3 open-label extension study is currently ongoing (PA0012). As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 to the SmPC have been updated. The package leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.2 rev.1. As part of the application the MAH is requesting a 1-year extension of the market protection.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023, 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.5. Cosentyx - secukinumab - EMEA/H/C/003729/II/0090

Novartis Europharm Limited

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Monica Martinez Redondo

Scope: "Extension of indication to include treatment of Hidradenitis Suppurativa (HS) for Cosentyx, based on results from two Phase 3 studies CAIN457M2301 (SUNSHINE) and CAIN457M2302 (SUNRISE). These studies are multi-center, randomized, double-blind, placebo-controlled, parallel group Phase 3 studies conducted to assess the short (16 weeks) and long-term (up to 52 weeks) efficacy and safety of two secukinumab dose regimens (Q2W or Q4W) compared to placebo in adult subjects with moderate to severe HS. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11.1 of the RMP has also been approved."

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023, 15.12.2022, 15.09.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP noted the letter of recommendations dated 14 April 2023.

The summary of opinion was circulated for information.

5.1.6. Epidyolex - cannabidiol - Orphan - EMEA/H/C/004675/II/0020

GW Pharma (International) B.V.

Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Tomas Radimersky, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Update of section 4.8 of the SmPC to provide further details regarding the increased risk of pneumonia. In addition, the outcome of the P46 011.1 procedure, as concluded in January 2023, is reflected in section 5.1 of the SmPC. The MAH took the opportunity to implement editorial changes in the product information and the local representative contacts in the Package Leaflet were updated. Version 3.0 of the RMP has also been agreed."

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023, 15.12.2022, 15.09.2022.

The CHMP noted that the MAH withdrew the extension of indication part from the scope of the variation.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP adopted the similarity assessment report.

5.1.7. Ervebo - recombinant vesicular stomatitis virus - Zaire Ebolavirus vaccine (live) - EMEA/H/C/004554/II/0025

Merck Sharp & Dohme B.V.

Rapporteur: Christophe Focke, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include the paediatric population from 1 year to less than 18 years of age based on final results from study V920-016 (PREVAC); this is a phase 2, randomized, double-blind, placebo-controlled study of 2 leading Ebola vaccine candidates (Ad26.ZEBOV/MVA-BN-Filo and V920) and 3 vaccine strategies (Ad26.ZEBOV/MVABN-Filo, 1-dose V920, and 2 dose V920) to evaluate immunogenicity and safety in healthy children and adolescents from 1 to 17 years of age and adults 18 years of age and older. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the Annex II and the list of local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 10.11.2022.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.8. Iclusig - ponatinib - Orphan - EMEA/H/C/002695/II/0064

Incyte Biosciences Distribution B.V.

Rapporteur: Filip Josephson, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include treatment of newly diagnosed adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), either with Iclusig (ponatinib) in combination with chemotherapy, or with Iclusig (ponatinib) monotherapy after corticosteroid induction in patients not eligible to receive chemotherapy-based regimens, based on final results from studies AP24534-11-001 and INCB 84344-201. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 22 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 10.11.2022.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.9. Jardiance - empagliflozin - EMEA/H/C/002677/II/0076

Boehringer Ingelheim International GmbH

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension of indication for Jardiance to include treatment of children aged 10 years and above with type 2 diabetes based on results from study DINAMO 1218-0091; this is a double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 21.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.10. Moventig - naloxegol - EMEA/H/C/002810/II/0039

Kyowa Kirin Holdings B.V.

Rapporteur: Christophe Focke, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update information regarding the use of naloxegol in OIC patients with cancer-related pain based on real-world data from non-interventional studies (NACASY, KYONAL, and MOVE studies), post-marketing data, and literature. The Package Leaflet is updated accordingly. The RMP

version 8 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.11. Opdivo - nivolumab - EMEA/H/C/003985/II/0117

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include Opdivo in combination with platinum-based chemotherapy for neoadjuvant treatment of adult patients with resectable stage IB-IIIA non-small cell lung cancer (NSCLC), based on results from study CA209816; a randomised, open-label, phase 3 trial of nivolumab plus ipilimumab or nivolumab plus platinum-doublet chemotherapy versus platinum-doublet chemotherapy in early-stage NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 27.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 23.02.2023, 13.10.2022, 23.06.2022.

See 2.3

The Committee discussed the issues identified in this application.

An oral explanation was held on 24 April 2023. The presentation by the applicant focused on the clinical data in support of the application.

The Committee adopted a 4th request for supplementary information with a specific timetable.

5.1.12. Opdivo - nivolumab - EMEA/H/C/003985/II/0125/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include adolescent patients aged 12 years and older in treatment of advanced (unresectable or metastatic) melanoma (nivolumab monotherapy), treatment of advanced (unresectable or metastatic) melanoma (nivolumab in combination with ipilimumab) and adjuvant treatment of melanoma (nivolumab monotherapy) for Opdivo, based on results from a nonclinical biomarker study (Expression of PD-L1 (CD274), and characterization of tumour infiltrating immune cells in tumours of paediatric origin), also based on results from a Phase 1/2 clinical study (CA209070, A Phase 1/2 Study of Nivolumab (Ind# 124729) In Children, Adolescents, And Young Adults With Recurrent Or Refractory Solid Tumors As A Single Agent And In Combination With Ipilimumab) and a modelling and simulation study. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 30.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.13. Revestive - teduglutide - Orphan - EMEA/H/C/002345/II/0054/G

Takeda Pharmaceuticals International AG Ireland Branch

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Extension of indication to include patients from 4 months corrected gestational aged 1 year and above. Consequently, sections 4.1, 4.2, 4.8, 5.1 and 5.2 are updated. The package leaflet is updated accordingly.
Update of annex II to amend the date of completion of the post-authorisation study. The MAH took the opportunity to also amend local representatives."

Action: For adoption

Request for Supplementary Information adopted on 15.09.2022, 22.04.2022, 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.14. RoActemra - tocilizumab - EMEA/H/C/000955/II/0114

Roche Registration GmbH

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer

Scope: "Extension of indication to include treatment of new indication for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) for RoActemra, based on final results from the pivotal Phase III study WA29767 (focuSSced) entitled, "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis" and the supportive Phase II/III study WA27788 (faSScinate) entitled, "A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis".
As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 28 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 15.12.2022.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.15. Ronapreve - casirivimab / imdevimab - EMEA/H/C/005814/II/0002

Roche Registration GmbH

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg and receiving supplemental oxygen, who have a negative SARS-CoV-2 antibody test result for Ronapreve; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.1, 5.2 and 6.6 of the SmPC are updated.
The variation leads to amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP).", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 23.02.2023, 13.10.2022, 19.05.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.16. Spikevax - elasomeran - EMEA/H/C/005791/II/0097/G

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Grouped variation:
- C.I.6.a (Type II): Extension of indication to include a 25 µg booster dose of Spikevax bivalent Original/Omicron BA.4-5 (12.5 µg elasomeran /12.5 µg davesomeran) in children aged 6 through 11 years of age; as a consequence, sections 2, 4.1, 4.2, 4.4 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. A revised RMP version 6.5 has been approved.
- C.I.z (Type II): Update of sections 4.8 and 5.1 of the Spikevax bivalent Original/Omicron BA.1 SmPC to add median follow-up period and D91 persistence data, based on Parts F and G (mRNA- 1273.214) of study mRNA-1273-P205 (NCT04927065), an open-label Phase 2/3 study evaluating the immunogenicity and safety of variant-targeting booster candidate vaccines. The Package Leaflet is updated accordingly.
- C.I.z (Type II): To update sections 4.8 and 5.1 of the Spikevax bivalent Original/Omicron BA.4-5 SmPC to add ADR details and clinical data, based on Part H (mRNA- 1273.222) of study mRNA-1273-P205 (NCT04927065), an open-label Phase 2/3 study evaluating the immunogenicity and safety of variant-targeting booster candidate vaccines.
In addition, the Marketing authorisation holder took the opportunity to implement a number of editorial changes to the product information."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.17. Vemlidy - tenofovir alafenamide - EMEA/H/C/004169/II/0040

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Valentina Di Giovanni

Scope: "Extension of indication to include treatment of chronic hepatitis B-infected children from 6 years and older and weighing at least 25 kilograms for Vemlidy, based on the interim results from Week 24 clinical study report (CSR) for Cohort 1 and Cohort 2 Group 1 and supporting modular summaries for the category 3 study GS-US-320-1092, 'A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection'. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.
In addition, the MAH took the opportunity to update the wording in section 4.6 of the SmPC related to breastfeeding and pregnancies exposed to TAF, and to update the contact details of the local representative in Romania in the Package Leaflet.
An updated RMP version 9.1 has been provided."

Action: For adoption

Request for Supplementary Information adopted on 26.01.2023, 15.09.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.18. Xromi - hydroxycarbamide - EMEA/H/C/004837/II/0019

Nova Laboratories Ireland Limited

Rapporteur: Anastasia Mountaki, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Jo Robays

Scope: "Extension of indication to include the prevention of vaso-occlusive complications of sickle cell disease in children from 6 months to 2 years of age for Xromi, based on final results from the paediatric study INV543, listed as a category 3 study in the RMP; this is a single-arm, open-label, multi-center study in children with sickle cell anaemia over 6 months of age. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.19. Yervoy - ipilimumab - EMEA/H/C/002213/II/0100

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include in combination with nivolumab the treatment of adolescents (12 years of age and older) for advanced (unresectable or metastatic) melanoma, based on the pivotal study CA209070; this is a multicentre, open-label, single arm, phase 1/2 trial of nivolumab +/- ipilimumab in children, adolescents and young adults with recurrent or refractory solid tumours or lymphomas. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 38.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

6.1.1. human albumin solution / gentamicin sulfate - EMEA/H/D/006141

human assisted reproductive techniques including in-vitro fertilisation procedures

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 10.11.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

6.1.2. gentamicin sulfate / sargramostim / heparin sodium / insulin human - EMEA/H/D/006090

human assisted reproductive techniques including in-vitro fertilisation procedures

Scope: Request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in March 2023.

Action: For adoption

List of Outstanding Issues adopted on 30.03.2023. List of Questions adopted on 13.10.2022.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of outstanding issues adopted in March 2023.

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

6.3.1. in vitro diagnostic medical device - EMEA/H/D/006255

is indicated as an aid in the selection of adult haemophilia A patients for whom valoctocogene roxaparvovec treatment is being considered

Scope: Request for supplementary information

Action: For information

The CHMP noted the request for supplementary information, which was adopted by CAT.

6.3.2. in vitro diagnostic medical device - EMEA/H/D/006233

To determine HER2 (Human Epidermal Growth Factor Receptor 2) oncoprotein status

Scope: Opinion

Action: For adoption

Request for supplementary information adopted on 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report.

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

The CHMP noted the list of applications received.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 2 recommendations for eligibility to PRIME: 1 was granted and 1 denied.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0043, Orphan

EUSA Pharma (Netherlands) B.V.

Rapporteur: Johann Lodewijk Hillege

Scope: "Update of sections 4.1, 4.2 and 5.1 of the SmPC based on final results from study APN311-202V3 listed as a Specific Obligation in the Annex II of the Product Information. This is a Phase I/II dose schedule finding study of Ch14.18/CHO continuous infusion combined with subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma. In addition, the MAH took the opportunity to update Annex II section E. The Package Leaflet is updated accordingly."

Action: For information

Request for Supplementary Information adopted on 15.09.2022.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

9.1.2. Inpremzia - insulin human (rDNA) - EMEA/H/C/005331

Baxter Holding B.V.; treatment of patients with diabetes mellitus who require intravenous insulin

Rapporteur: Christian Gartner, Co-Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Withdrawal of marketing authorisation

Action: For information

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

The CHMP noted the withdrawal of the marketing authorisation.

9.1.3. Hepcludex - bulevirtide - EMEA/H/C/004854/II/0019, Orphan

Gilead Sciences Ireland Unlimited Company

Rapporteur: Filip Josephson

Scope: "Update of sections 4.8 and 5.1 of the SmPC in order to update the list of adverse drug reactions (ADRs) and efficacy information based on interim results from study MYR301 listed as a Specific Obligation in the Annex II of the Product Information; this is a Multicenter, Open-label, Randomized Phase III Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients with Chronic Hepatitis Delta. Consequently, the MAH proposes a switch from conditional marketing authorisation to full marketing authorisation given the

fulfilment of the SOB. The Package Leaflet is updated accordingly.
In addition, the MAH took the opportunity to implement editorial changes in the SmPC."

Action: For adoption

Request for Supplementary Information adopted on 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

9.1.4. Ofev - nintedanib - EMEA/H/C/003821/X/0052/G

Boehringer Ingelheim International GmbH

Rapporteur: Finbarr Leacy, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Type II variation - update of SmPC sections 4.2, 5.1 and 5.2 (former line extension with extension of indication in children 6 to 17 years old)."

Action: For adoption

List of Questions adopted on 26.01.2023.

The Committee discussed the issues identified in this application. The CHMP was reminded that the extension of indication application part has been withdrawn and therefore the remaining scope is a normal type II variation.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.5. Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0033

AstraZeneca AB

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Update of sections 4.2, 5.1 and 5.2 of the SmPC and the package leaflet based on results from study PK/PD study listed as a specific obligation in the Annex II in order to fulfil SOB 001 and SOB 003; this is a PK and PK/PD Analysis of Intravenously Administered Andexanet after dosing to steady state with a factor Xa inhibitor, rivaroxaban or apixaban, in healthy subjects and patients who have acute major bleeding. In addition, the MAH took the opportunity to implement editorial changes in Annex II of the SmPC. The RMP version 3.0 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 26.01.2023, 13.10.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

9.1.6. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0056

Orexigen Therapeutics Ireland Limited

Scope: Request for re-examination, appointment of re-examination rapporteur

Action: For adoption

Opinion adopted on 30.03.2023. Request for Supplementary Information adopted on 26.01.2023, 15.09.2022, 24.03.2022.

The CHMP noted the request for re-examination and appointed a re-examination rapporteur.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

10.1.1. Adakveo - crizanlizumab - EMEA/H/A-20/1525

Novartis Europharm Limited

Referral Rapporteur: Daniela Philadelphy, Referral Co-Rapporteur: Johanna Lähteenvuo

Scope: The European Commission (EC) initiated a procedure under Article 20 of Regulation (EC) No 726/2004 and requested the Agency/CHMP to assess the benefit-risk balance of the centrally authorised medicinal product Adakveo (crizanlizumab) in its approved indication. In addition, the EC requested the Agency/CHMP to considere as soon as possible whether temporary measures were necessary to protect public health.

The initiation of the review follows preliminary results from the Phase III study (CSEG101A2301, STAND) which is a specific obligation to the conditional marketing authorisation for Adakveo. The preliminary results for STAND study show no superiority of crizanlizumab over placebo in annualised rates of vaso-occlusive crises leading to a healthcare visit over the first-year post randomisation.

Action: For adoption

List of questions adopted on 26.01.2023.

The Committee discussed the issues identified in this referral procedure.

The CHMP adopted a list of outstanding issues with a specific timetable.

Submission of responses: 03.05.2023

Re-start of the procedure: 08.05.2023

Rapporteur/co-rapporteur joint assessment report circulated to CHMP: 10.05.2023

Comments: 15.05.2023

Updated Rapporteur/co-rapporteur joint assessment report circulated to CHMP: 17.05.2023

CHMP Opinion: May 2023 CHMP

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.2.1. Colistimethate sodium (CMS) – EMEA/H/A-5(3)/1524

Various MAHs

Referral Rapporteur: Martina Weise, Referral Co-Rapporteur: Ewa Balkowiec Iskra

Review of the ratio of polymyxins E1 and E2 in colistin starting material and of the (sulfomethylation) composition profile of CMS finished product.

Scope: Revised timetable

Action: For adoption

The CHMP adopted the revised timetable.

Rapporteur/co-rapporteur assessment reports circulated to CHMP: 02.06.2023

Comments: 09.06.2023

Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 15.06.2023

CHMP list of questions/opinion: June 2023 CHMP

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

April 2023 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of

such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Vote by proxy

No topics

14.1.2. CHMP membership

The Chair announced that Petr Vrbata is the new alternate for Czechia, replacing Tomas Radimersky who took over the role of member for Czechia.

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for April 2023

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. Paediatric Committee (PDCO)

Draft agenda for the April 2023 PDCO meeting

Action: For information

The CHMP noted the agenda.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sean Barry

Reports from BWP April 2023 meeting to CHMP for adoption:

- 12 reports on products in scientific advice and protocol assistance
- 11 reports on products in pre-authorisation procedures
- 2 reports on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Election of Vice-Chairperson – Biologics Working Party

A call for nominations was launched at the March 2023 PROM meeting.

Nomination(s) received

Action: For election

The CHMP elected Francesca Luciani (IT) as vice-chair of the BWP.

14.3.3. Name Review Group (NRG)

Table of Decisions of the NRG meeting held on 26 April 2023.

Action: For adoption

The CHMP adopted the Table of Decisions.

14.3.4. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 11-14 April 2023. Table of conclusions

Action: For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

The CHMP noted the update.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

No items

List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 24-26 April 2023 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Daniela Philadelphy	Member	Austria	No interests declared	
Christian Gartner	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Emilia Mavrokordatou	Alternate	Cyprus	No participation in final deliberations and voting on:	COVID-19 vaccines
Tomas Radimersky	Member	Czechia	No interests declared	
Petr Vrbata	Alternate	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No interests declared	
Aaron Sosa Mejia	Alternate	Denmark	No restrictions applicable to this meeting	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantina Alexopoulou	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Robert Porszasz	Member	Hungary	No interests declared	
Beata Maria Jakline Ullrich	Alternate	Hungary	No interests declared	
Hjalti Kristinsson	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Finbarr Leacy	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Maria Grazia Evandri	Alternate	Italy	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Elita Poplavska	Member	Latvia	No interests declared	
Vilma Petrikaite	Member	Lithuania	No interests declared	
Larisa Gorobets	Alternate	Lithuania	No restrictions applicable to this meeting	
Martine Trauffler	Member	Luxembourg	No interests declared	
Alexandra Branchu	Alternate	Luxembourg	No restrictions applicable to this meeting	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on:	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Frantisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Kristina Nadrah	Member	Slovenia	No restrictions applicable to this meeting	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Bruno Delafont	Co-opted member	France	No participation in discussion, final deliberations and voting on:	Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0033
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Nora Cascante Estepa	Expert	Germany	No interests declared	
Sabine Mayrhofer	Expert	Germany	No interests declared	
Irene Bachmann	Expert	Germany	No interests declared	
Martijn van Gils	Expert	Netherlands	No interests declared	
Carla Herberts	Expert	Netherlands	No interests declared	
Vincent Gazin	Expert	France	No interests declared	
Karri Penttila	Expert	Finland	No interests declared	
Charlotte Anderberg	Expert	Sweden	No interests declared	
Helena Fridborg	Expert	Sweden	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Jenny-Maria Jönsson	Expert	Sweden	No participation in final deliberations and voting on:	Opdivo - nivolumab - EMEA/H/C/003985/II/0117 Opdivo - nivolumab - EMEA/H/C/003985/II/0125/G
Karin Fjordén	Expert	Sweden	No restrictions applicable to this meeting	
Farshid Jalalvand	Expert	Sweden	No interests declared	
Kristian Wennmalm	Expert	Sweden	No interests declared	
Daiana Vasilcanu	Expert	Sweden	No interests declared	
Bernice Aronsson	Expert	Sweden	No interests declared	
Mair Powell	Expert	Ireland	No interests declared	
Agnieszka Przybyszewska	Expert	Ireland	No interests declared	
Olive Smyth	Expert	Ireland	No interests declared	
Catherine Byrne	Expert	Ireland	No interests declared	
Liam McDonough	Expert	Ireland	No interests declared	
Brian Aylward	Expert	Ireland	No interests declared	
Juta Kraav	Expert	Estonia	No restrictions applicable to this meeting	
Sargi Caizergues Lama	Expert	France	No interests declared	
Simin Oveisi	Expert	France	No restrictions applicable to this meeting	
Umberto Casalegno	Expert	France	No interests declared	
Elisabeth Wischnitzki	Expert	Austria	No interests declared	
Angelina Doriguzzi	Expert	Austria	No restrictions applicable to this meeting	
Susanne Urach	Expert	Austria	No interests declared	
Brigitte Mueller	Expert	Austria	No interests declared	
Harald Bernsteiner	Expert	Austria	No interests declared	
Christine Vaculik	Expert	Austria	No interests declared	
Matthias Braun	Expert	Austria	No interests declared	
Rene Anour	Expert	Austria	No interests declared	
Tobias Gluexam	Expert	Austria	No interests declared	
Silke Dorner	Expert	Austria	No interests declared	
Ilona Reischl	Expert	Austria	No interests declared	
Walter-Johannes Beiersdorf	Expert	Austria	No restrictions applicable to this meeting	
Helga Sgardelli	Expert	Austria	No interests declared	
Karl Katholnig	Expert	Austria	No restrictions applicable to this meeting	
Philipp Janesch	Expert	Austria	No interests declared	
Claudia Reichelt	Expert	Austria	No interests declared	
Maria Victoria Tudanca Pacios	Expert	Spain	No restrictions applicable to this meeting	
Paula Contreras Alarcón	Expert	Spain	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Carolina Prieto Fernandez	Expert	Spain	No interests declared	
Lucia Lopez-Anglada Fernandez	Expert	Spain	No interests declared	
Tomas Arroyo Perez	Expert	Spain	No interests declared	
Macarena Rodriguez Mendizabal	Expert	Spain	No interests declared	
Laura Rodriguez Garcia	Expert	Spain	No interests declared	
Nathalie Parij	Expert	Belgium	No interests declared	
Stefan Bonné	Expert	Belgium	No interests declared	
Valerie Lescrainier	Expert	Belgium	No interests declared	
Violette Dirix	Expert	Belgium	No interests declared	
Marta Romano	Expert	Belgium	No interests declared	
Ingrid Bourges	Expert	Belgium	No interests declared	
Paolo Foggi	Expert	Italy	No interests declared	
Adriana Ammassari	Expert	Italy	No interests declared	
Luca Santi	Expert	Italy	No restrictions applicable to this meeting	
Martina Perini	Expert	Italy	No restrictions applicable to this meeting	
Odoardo Maria Olimpieri	Expert	Italy	No interests declared	
Federico De Angelis	Expert	Italy	No interests declared	
Alessandro Assisi	Expert	Italy	No interests declared	
Pia Rivetti di Val Cervo	Expert	Italy	No interests declared	
Gabriella Passacquale	Expert	Italy	No interests declared	
Valentina Conti	Expert	Italy	No interests declared	
Antonella Isgrò	Expert	Italy	No interests declared	
Giancarlo Zito	Expert	Italy	No interests declared	
Sofia Kapanadze	Expert	Germany	No interests declared	
Bettina Klug	Expert	Germany	No interests declared	
Jorg Engelbergs	Expert	Germany	No interests declared	
Hilke Zander	Expert	Germany	No interests declared	
Sara Tognarelli	Expert	Germany	No restrictions applicable to this meeting	
Linda Marchioro	Expert	Germany	No interests declared	
Emilie Birch Kristensen	Expert	Denmark	No restrictions applicable to this meeting	
Anne Hasle Buur	Expert	Denmark	No interests declared	
Kristina Bech Jensen	Expert	Denmark	No interests declared	
Mette Linnert Jensen	Expert	Denmark	No interests declared	
Torsten Holm Nielsen	Expert	Denmark	No restrictions applicable to this meeting	
Ebru Karakoc Madsen	Expert	Denmark	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Martin Oleksiewicz	Expert	Denmark	No interests declared	
Ann-Cathrine Dunvald	Expert	Denmark	No interests declared	
Line Praest Lauridsen	Expert	Denmark	No restrictions applicable to this meeting	
Boje Kvorning Pires Ehmsen	Expert	Denmark	No interests declared	
Jacob Alsbæk Olsen	Expert	Denmark	No restrictions applicable to this meeting	
Deirdre Mannion	Expert	Denmark	No restrictions applicable to this meeting	
Kristin Skougaard	Expert	Denmark	No interests declared	
Kommerie Hendrik	Expert	Netherlands	No interests declared	
Loes den Otter	Expert	Netherlands	No interests declared	
Elly Vereyken	Expert	Netherlands	No interests declared	
Alida Spruijt	Expert	Netherlands	No interests declared	
Karolina Kwiatek	Expert	Netherlands	No interests declared	
Monique van Raamsdonk	Expert	Netherlands	No interests declared	
Angela de Kleynen	Expert	Netherlands	No interests declared	
Illiana Meurs	Expert	Netherlands	No interests declared	
Inger Mulder-van Dam	Expert	Netherlands	No interests declared	
Hinke Johanna Van der Woude	Expert	Netherlands	No interests declared	
Laura Rodwell	Expert	Netherlands	No interests declared	
Evelien Minten	Expert	Netherlands	No interests declared	
Susanne Breedijk-van den Ende	Expert	Netherlands	No interests declared	
Taco Monster	Expert	Netherlands	No interests declared	
Melanie Diane Klok	Expert	Netherlands	No interests declared	
Adrian Post	Expert	Netherlands	No interests declared	
Michelle van der Grift	Expert	Netherlands	No interests declared	
Patrick Vrijlandt	Expert	Netherlands	No interests declared	
Jorn Mulder	Expert	Netherlands	No interests declared	
Esther Brandon	Expert	Netherlands	No interests declared	
Louise Claessen	Expert	Netherlands	No interests declared	
Quirine Fillekes	Expert	Netherlands	No interests declared	
Mark van Bussel	Expert	Netherlands	No interests declared	
Esther Broekman	Expert	Netherlands	No restrictions applicable to this meeting	
Kairi Rooma	Expert	Estonia	No interests declared	
Simona Teodosiu	Expert	France	No interests declared	
Vita Gulevska	Expert	Latvia	No interests declared	
Ieva Rutkovska	Expert	Latvia	No interests declared	
Elmer Schabel	Expert	Germany	No interests declared	
Sheila Killalea	Expert	Ireland	No interests declared	
Emmely de Vries	Expert	Netherlands	No interests declared	
Katrien Oude Rengerink	Expert	Netherlands	No interests declared	
Sanne ten Dam	Expert	Netherlands	No interests declared	
Daniel Fernández Soto	Expert	Spain	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Anissa Benlazar	Expert	France	No interests declared	
Maria Martinez Gonzalez	Expert	Spain	No interests declared	
Marte Fergestad	Expert	Norway	No interests declared	
Maja Sommerfelt Grønvold	Expert	Norway	No interests declared	
Hannah Münch	Expert	Austria	No interests declared	
Anne-Marie Dalseg	Expert	Denmark	No interests declared	
Edwige Haelterman Brenneisen	Expert	Belgium	No interests declared	
Francesca Luciani	Expert	Italy	No interests declared	
Georgia Valsami	Expert	Greece	No interests declared	
Maria Dimopoulou	Expert	Greece	No participation in final deliberations and voting on:	Adakveo - crizanlizumab - EMEA/H/A-20/1525
A representative from the European Commission attended the meeting				
Meeting run with the help of EMA staff				

Experts were evaluated against the agenda topics or activities they participated in.

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

06 July 2023
EMA/CHMP/192734/2023

Annex to 24-26 April 2023 CHMP Minutes

Pre-submission and post-authorisations issues

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for April 2023: **For adoption**	Adopted

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for April 2023: **For adoption**	Adopted

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Ceplene - histamine dihydrochloride - EMEA/H/C/000796/S/0045 Laboratoires Delbert, Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances.
ELZONRIS - tagraxofusp - EMEA/H/C/005031/S/0020, Orphan Stemline Therapeutics B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances.
SCENESSE - afamelanotide - EMEA/H/C/002548/S/0045, Orphan Clinuvel Europe Limited, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber Request for Supplementary Information adopted on 26.04.2023.	Request for supplementary information adopted with a specific timetable.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Braftovi - encorafenib - EMEA/H/C/004580/R/0029 Pierre Fabre Medicament, Rapporteur: Janet Koenig, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Rugile Pilviniene Request for Supplementary Information adopted on 23.02.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Buvidal - buprenorphine - EMEA/H/C/004651/R/0021 Camurus AB, Rapporteur: Finbarr Leacy, PRAC Rapporteur: Tiphaine Vaillant Request for Supplementary Information adopted on 26.04.2023.	Request for supplementary information adopted with a specific timetable.
Deferiprone Lipomed - deferiprone - EMEA/H/C/004710/R/0011 Lipomed GmbH, Generic, Generic of Ferriprox, Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Tiphaine Vaillant Request for Supplementary Information adopted on 23.02.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Delstrigo - doravirine / lamivudine / tenofovir disoproxil - EMEA/H/C/004746/R/0034 Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Gefitinib Mylan - gefitinib - EMEA/H/C/004826/R/0008 Mylan Pharmaceuticals Limited, Generic, Generic of Iressa, Rapporteur: Margareta Bego, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Jivi - damoctocog alfa pegol - EMEA/H/C/004054/R/0027 Bayer AG, Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Menno van der Elst	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that

	the renewal of the marketing authorisation can be granted with unlimited validity.
Kigabeq - vigabatrin - EMEA/H/C/004534/R/0012 ORPHELIA Pharma SAS, Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Kirsti Villikka Request for Supplementary Information adopted on 30.03.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Lenalidomide Accord - lenalidomide - EMEA/H/C/004857/R/0021 Accord Healthcare S.L.U., Generic, Generic of Revlimid, Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Tiphaine Vaillant Request for Supplementary Information adopted on 26.04.2023.	Request for supplementary information adopted with a specific timetable.
Mektovi - binimetinib - EMEA/H/C/004579/R/0024 Pierre Fabre Medicament, Rapporteur: Janet Koenig, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Inês Ribeiro-Vaz Request for Supplementary Information adopted on 23.02.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Pelgraz - pegfilgrastim - EMEA/H/C/003961/R/0040 Accord Healthcare S.L.U., Rapporteur: Sol Ruiz, Co-Rapporteur: Petr Vrbata, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 30.03.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Pifeltro - doravirine - EMEA/H/C/004747/R/0027 Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Venclyxto - venetoclax - EMEA/H/C/004106/R/0046 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Eva Jirsová Request for Supplementary Information adopted on 26.04.2023.	Request for supplementary information adopted with a specific timetable.
Verzenios - abemaciclib -	Positive Opinion adopted by consensus together

EMEA/H/C/004302/R/0025 Eli Lilly Nederland B.V., Rapporteur: Filip Josephson, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Inês Ribeiro-Vaz Request for Supplementary Information adopted on 30.03.2023.	with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
VEYVONDI - vonicog alfa - EMEA/H/C/004454/R/0027 Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Mari Thorn Request for Supplementary Information adopted on 23.02.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Ziextenzo - pegfilgrastim - EMEA/H/C/004802/R/0025 Sandoz GmbH, Rapporteur: Christian Gartner, Co-Rapporteur: Simona Badoi, PRAC Rapporteur: Menno van der Elst	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

B.2.3. Renewals of Conditional Marketing Authorisations

Abecma - idecabtagene vicleucel - EMEA/H/C/004662/R/0029, Orphan, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Rune Kjeken, Co-Rapporteur: Heli Suila, CHMP Coordinators: Ingrid Wang and Johanna Lähteenvuo, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan GlaxoSmithKline (Ireland) Limited, Rapporteur: Johanna Lähteenvuo, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 26.04.2023.	Request for supplementary information adopted with a specific timetable.
Dovprela - pretomanid - EMEA/H/C/005167/R/0015, Orphan Mylan IRE Healthcare Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Liana Gross-Martirosyan	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.

Hepcludex - bulevirtide - EMEA/H/C/004854/R/0024, Orphan Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson, PRAC Rapporteur: Adam Przybylkowski	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Idefirix - imlifidase - EMEA/H/C/004849/R/0014, Orphan Hansa Biopharma AB, Rapporteur: Martina Weise, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 26.04.2023.	Request for supplementary information adopted with a specific timetable.
ROCTAVIAN - valoctocogene roxaparvovec - EMEA/H/C/005830/R/0003, Orphan, ATMP BioMarin International Limited, Rapporteur: Violaine Closson Carella, Co-Rapporteur: Silke Dorner, CHMP Coordinators: Jean-Michel Race and Daniela Philadelphy, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 21.04.2023.	Request for supplementary information adopted with a specific timetable.
Rozlytrek - entrectinib - EMEA/H/C/004936/R/0015 Roche Registration GmbH, Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 30.03.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its April 2023 meeting:	
EMEA/H/C/PSUSA/00009329/202208 (vemurafenib) CAPS: **Zelboraf** (EMEA/H/C/002409) (vemurafenib), Roche Registration GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "17/08/2019 To: 16/08/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s):

	Update of section 4.8 of the SmPC to add the adverse reaction thrombocytopenia with a frequency common. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010055/202209 (alemtuzumab) CAPS: **Lemtrada** (EMEA/H/C/003718) (alemtuzumab), Sanofi Belgium, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Anette Kirstine Stark, "12/09/2021 To: 12/09/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction: "alopecia areata" with a frequency [uncommon]. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010118/202209 (midazolam (oromucosal solution, treatment of prolonged, acute, convulsive seizures)) CAPS: **BUCCOLAM** (EMEA/H/C/002267) (midazolam), Laboratorios Lesvi S.L., Rapporteur: Johann Lodewijk Hillege NAPS: **NAPs** - EU PRAC Rapporteur: Liana Gross-Martirosyan, "09/09/2019 To: 09/09/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of section 4.8 of the SmPC to add anaphylactic reaction with a frequency not known. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010366/202209 (naltrexone / bupropion) CAPS: **Mysimba** (EMEA/H/C/003687) (naltrexone hydrochloride / bupropion hydrochloride), Orexigen Therapeutics Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "09/09/2021 To: 09/09/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 of the SmPC to add a warning/precaution on severe cutaneous adverse reactions, including acute generalised exanthematous pustulosis (AGEP), and section 4.8 of the SmPC to add the adverse reaction AGEP with a frequency not known. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010780/202209 (cemiplimab) CAPS:	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation

LIBTAYO (EMEA/H/C/004844) (cemiplimab), Regeneron Ireland Designated Activity Company (DAC), Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Menno van der Elst, "28/09/2021 To: 27/09/2022"	and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.2, 4.4 and 4.8 of the SmPC to add the adverse reaction haemophagocytic lymphohistiocytosis with a frequency unknown. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010880/202209 (bupivacaine/meloxicam) CAPS: **ZYNRELEF** (EMEA/H/C/005205) (bupivacaine / meloxicam), Heron Therapeutics, B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Liana Gross-Martirosyan, "24/03/2022 To: 23/09/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR, on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s): Update of section 4.6 of the SmPC to amend the available data on use during pregnancy, based on the PRAC advice for non-steroidal anti-inflammatory drugs (NSAID)-containing medicinal products (EMA/CMDh/642745/2022). The package leaflet is updated accordingly. Update of section 4.6 of the SmPC to amend the available data on use during lactation, based on the results of study HTX-011-220.
EMEA/H/C/PSUSA/00010882/202209 (amikacin (centrally authorised product only)) CAPS: **ARIKAYCE liposomal** (EMEA/H/C/005264) (amikacin), Insmed Netherlands B.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Jean-Michel Dogné, "28/09/2021 To: 27/09/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 of the SmPC to add a warning/precaution regarding an increased risk of aminoglycoside-associated ototoxicity in patients with mitochondrial rRNA mutations to the subsection Ototoxicity. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010940/202209 (ponesimod) CAPS: **PONVORY** (EMEA/H/C/005163) (ponesimod), Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Anette Kirstine Stark, "18/03/2022 To: 17/09/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add

	'seizure' in the tabulated list of adverse reactions with a frequency common. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010954/202209 (idecabtagene vicleucel) CAPS: **Abecma** (EMEA/H/C/004662) (idecabtagene vicleucel), Bristol-Myers Squibb Pharma EEIG, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, PRAC Rapporteur: Ulla Wändel Liminga, "26/03/2022 To: 25/09/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 of the SmPC to add warning information on Parkinsonism and to mention it in the footnotes of the table in section 4.8 of the SmPC for the SOC "Nervous system disorders".
EMEA/H/C/PSUSA/00010961/202209 (pralsetinib) CAPS: **GAVRETO** (EMEA/H/C/005413) (pralsetinib), Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga, "05/03/2022 To: 03/09/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction 'tuberculosis' with a frequency uncommon and a warning/precaution regarding tuberculosis. The package leaflet is updated accordingly.

B.4. EPARs / WPARs

BIMERVAX - sars-cov-2 virus, variants b.1.351-b.1.1.7, spike protein, receptor binding domain fusion heterodimer - EMEA/H/C/006058 Hipra Human Health S.L., immunisation to prevent COVID-19 caused by SARS-CoV-2, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Dabigatran Etexilate Accord - dabigatran etexilate - EMEA/H/C/005639 Accord Healthcare S.L.U., prevention of venous thromboembolic events, Generic, Generic of Pradaxa, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Epysqli - eculizumab - EMEA/H/C/006036 Samsung Bioepis NL B.V., treatment of	For information only. Comments can be sent to the PL in case necessary.

paroxysmal nocturnal haemoglobinuria, Similar biological application (Article 10(4) of Directive No 2001/83/EC)	
Lacosamide Adroiq - lacosamide - EMEA/H/C/006047 Extrovis EU Ltd., treatment of epilepsy, Generic, Generic of Vimpat, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Omvoh - mirikizumab - EMEA/H/C/005122 Eli Lilly Nederland B.V., treatment of moderately to severely active ulcerative colitis, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Pedmarqsi - sodium thiosulfate - EMEA/H/C/005130, PUMA Fennec Pharmaceuticals (EU) Limited, for the prevention of ototoxicity induced by cisplatin (CIS) chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic, solid tumours., Known active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Qaialdo - spironolactone - EMEA/H/C/005535 Nova Laboratories Ireland Limited, management of refractory oedema, Hybrid application (Article 10(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Sugammadex Adroiq - sugammadex - EMEA/H/C/006046 Extrovis EU Ltd., reversal of neuromuscular blockade induced by rocuronium or vecuronium, Generic, Generic of Bridion, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Advate - octocog alfa - EMEA/H/C/000520/II/0119/G Takeda Manufacturing Austria AG, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 26.04.2023.	Request for supplementary information adopted with a specific timetable.
Bexsero - meningococcal group B vaccine	Positive Opinion adopted by consensus on

(recombinant, component, adsorbed) - EMEA/H/C/002333/II/0118 GSK Vaccines S.r.l, Rapporteur: Filip Josephson Opinion adopted on 14.04.2023.	14.04.2023.
Grepid - clopidogrel - EMEA/H/C/001059/II/0054 Pharmathen S.A., Generic, Generic of Plavix, Rapporteur: Kristina Nadrah Opinion adopted on 26.04.2023. Request for Supplementary Information adopted on 26.01.2023, 15.09.2022.	Positive Opinion adopted by consensus on 26.04.2023.
Idefirix - imlifidase - EMEA/H/C/004849/II/0013, Orphan Hansa Biopharma AB, Rapporteur: Martina Weise Opinion adopted on 14.04.2023.	Positive Opinion adopted by consensus on 14.04.2023.
Instanyl - fentanyl - EMEA/H/C/000959/II/0075 Takeda Pharma A/S, Rapporteur: Alexandre Moreau Opinion adopted on 14.04.2023. Request for Supplementary Information adopted on 02.03.2023.	Positive Opinion adopted by consensus on 14.04.2023.
Ivabradine Zentiva - ivabradine - EMEA/H/C/004117/II/0014 Zentiva k.s., Generic, Generic of Procoralan, Rapporteur: Tomas Radimersky Opinion adopted on 20.04.2023. Request for Supplementary Information adopted on 12.01.2023.	Positive Opinion adopted by consensus on 20.04.2023.
Kevzara - sarilumab - EMEA/H/C/004254/II/0036/G Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 26.04.2023.	Request for supplementary information adopted with a specific timetable.
Luminity - perflutren - EMEA/H/C/000654/II/0042/G Lantheus EU Limited, Rapporteur: Finbarr Leacy Opinion adopted on 26.04.2023. Request for Supplementary Information adopted on 15.12.2022.	Positive Opinion adopted by consensus on 26.04.2023.
Mounjaro - tirzepatide - EMEA/H/C/005620/II/0004/G Eli Lilly Nederland B.V., Rapporteur: Martina Weise Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 20.04.2023.	
Ocrevus - ocrelizumab - EMEA/H/C/004043/II/0036/G Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 20.04.2023. Request for Supplementary Information adopted on 09.02.2023.	Positive Opinion adopted by consensus on 20.04.2023.
Ontruzant - trastuzumab - EMEA/H/C/004323/II/0045 Samsung Bioepis NL B.V., Rapporteur: Karin Janssen van Doorn Opinion adopted on 14.04.2023.	Positive Opinion adopted by consensus on 14.04.2023.
POTELIGEO - mogamulizumab - EMEA/H/C/004232/II/0018, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Johann Lodewijk Hillege Opinion adopted on 26.04.2023.	Positive Opinion adopted by consensus on 26.04.2023.
POTELIGEO - mogamulizumab - EMEA/H/C/004232/II/0019/G, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Johann Lodewijk Hillege Opinion adopted on 26.04.2023.	Positive Opinion adopted by consensus on 26.04.2023.
POTELIGEO - mogamulizumab - EMEA/H/C/004232/II/0020, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 14.04.2023.	Request for supplementary information adopted with a specific timetable.
Surgiflo Haemostatic Matrix Kit - human thrombin - EMEA/H/D/002301/II/0033/G Ferrosan Medical Devices A/S, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 20.04.2023.	Request for supplementary information adopted with a specific timetable.
Taltz - ixekizumab - EMEA/H/C/003943/II/0049/G Eli Lilly and Co (Ireland) Limited, Rapporteur: Kristina Dunder Opinion adopted on 20.04.2023.	Positive Opinion adopted by consensus on 20.04.2023.
Vyepti - eptinezumab - EMEA/H/C/005287/II/0005/G H. Lundbeck A/S, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 20.04.2023. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 20.04.2023.

on 09.02.2023.	
Vyepti - eptinezumab - EMEA/H/C/005287/II/0008 H. Lundbeck A/S, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 20.04.2023.	Positive Opinion adopted by consensus on 20.04.2023.
Vyvgart - efgartigimod alfa - EMEA/H/C/005849/II/0004/G, Orphan Argenx, Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 14.04.2023. Request for Supplementary Information adopted on 16.02.2023.	Positive Opinion adopted by consensus on 14.04.2023.
Zessly - infliximab - EMEA/H/C/004647/II/0028 Sandoz GmbH, Rapporteur: Eva Skovlund Opinion adopted on 14.04.2023.	Positive Opinion adopted by consensus on 14.04.2023.
Zutectra - human hepatitis B immunoglobulin - EMEA/H/C/001089/II/0058 Biotest Pharma GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 14.04.2023.	Positive Opinion adopted by consensus on 14.04.2023.
WS2365 **Ambirix-EMEA/H/C/000426/WS2365/0125** **Bexsero-EMEA/H/C/002333/WS2365/0119** **Cervarix-EMEA/H/C/000721/WS2365/0119** **Fendrix-EMEA/H/C/000550/WS2365/0081** **Infanrix hexa-EMEA/H/C/000296/WS2365/0326** **Synflorix-EMEA/H/C/000973/WS2365/0176** **Twinrix Adult-EMEA/H/C/000112/WS2365/0160** **Twinrix Paediatric-EMEA/H/C/000129/WS2365/0161** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 26.04.2023.	Positive Opinion adopted by consensus on 26.04.2023.
WS2444 **Lixiana-EMEA/H/C/002629/WS2444/0044** **Roteas-EMEA/H/C/004339/WS2444/0031** Daiichi Sankyo Europe GmbH, Lead Rapporteur: Maria Concepcion Prieto Yerro	Positive Opinion adopted by consensus on 26.04.2023.

Opinion adopted on 26.04.2023.	
WS2461/G **Blitzima-** **EMEA/H/C/004723/WS2461/0065/G** **Truxima-** **EMEA/H/C/004112/WS2461/0068/G** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz Opinion adopted on 26.04.2023.	Positive Opinion adopted by consensus on 26.04.2023.

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/II/0035 Baxalta Innovations GmbH, Rapporteur: Daniela Philadelphy, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on anaphylactic reaction and to add anaphylactic reaction to the list of adverse drug reactions (ADRs) with frequency Not Known, based on the cumulative review of MAH global database and literature search. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information." Request for Supplementary Information adopted on 14.04.2023.	Request for supplementary information adopted with a specific timetable.
Cosentyx - secukinumab - EMEA/H/C/003729/II/0097 Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola, "Update of section 4.8 of the SmPC in order to add 'pyoderma gangrenosum' to the list of adverse drug reactions (ADRs) with frequency 'not known' based on a systematic review of the MAH safety database, clinical trial data, literature search and epidemiological evaluation. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the Instructions for Use (IFU) of the pre-filled syringes (PFS) and to update the Additional Information (IFU videos) for PFS to the Cosentyx EU website." Opinion adopted on 26.04.2023.	Positive Opinion adopted by consensus on 26.04.2023.
Darzalex - daratumumab - EMEA/H/C/004077/II/0066, Orphan Janssen-Cilag International N.V., Rapporteur: Aaron Sosa Mejia, "Submission of the final	Positive Opinion adopted by consensus on 26.04.2023.

report from subgroup analysis of subjects with body weight >120 kg in ongoing randomized studies (MMY1004, MMY3012, MMY2040, and AMY3001) to further characterise the impact of body weight >120 kg on exposure and efficacy outcomes." Opinion adopted on 26.04.2023.	
Dupixent - dupilumab - EMEA/H/C/004390/II/0068 Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.8 and 5.1 of the SmPC to include long-term safety and efficacy information in children based on final results from study LTS14424 - EXCURSION. This is an interventional one-year study, to evaluate the long-term safety and tolerability of dupilumab in children 6 to 11 years of age with asthma, who participated in a previous dupilumab asthma clinical study EFC14153." Opinion adopted on 14.04.2023. Request for Supplementary Information adopted on 19.01.2023.	Positive Opinion adopted by consensus on 14.04.2023.
Enbrel - etanercept - EMEA/H/C/000262/II/0249 Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 4.6 of the SmPC in order to update information on breast feeding exposure based on the cumulative review of etanercept specific pharmacology, safety database and published medical literature. The Package Leaflet is updated accordingly. In addition, the MAH is taking this opportunity to correct minor administrative and typographical changes to the SmPC, Labelling and Package Leaflet. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 14.04.2023, 12.01.2023.	Request for supplementary information adopted with a specific timetable.
Evrysdi - risdiplam - EMEA/H/C/005145/II/0011, Orphan Roche Registration GmbH, Rapporteur: Bruno Sepodes, "Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to delete an existing warning on "Use with SMA gene therapy" and to update the safety profile and efficacy data in patients previously treated with other SMA-modifying	Positive Opinion adopted by consensus on 20.04.2023.

therapies based on the 24-month primary analysis data from study BP39054 (JEWELFISH); this is a multicenter, open-label study to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of risdiplam in adult and paediatric patients with SMA. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Opinion adopted on 20.04.2023. Request for Supplementary Information adopted on 26.01.2023.	
Fintepla - fenfluramine - EMEA/H/C/003933/II/0018, Orphan UCB Pharma SA, Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.8 and 5.1 of the SmPC in order to update the summary of the safety profile and list of adverse drug reactions for Dravet Syndrome and to update clinical efficacy information, following the assessment of the Article 46 procedure LEG/009 based on final results from atudy 3 (study 1501/1502 Part 2). The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 14.04.2023.	Request for supplementary information adopted with a specific timetable.
Galafold - migalastat - EMEA/H/C/004059/II/0038, Orphan Amicus Therapeutics Europe Limited, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.2 and 5.2 of the SmPC in order to modify administration instructions and to update the pharmacokinetic information based on study AT1001-045; a randomized, open-label, 6-way crossover study to evaluate the relative bioavailability of the 150-mg migalastat hydrochloride (HCl) capsule taken with caffeinated and sweetened beverages versus taken with water in healthy volunteers. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to introduce some minor editorial changes and additional corrections to the SmPC referring to prior regulatory procedures II/0030 and II/0034." Opinion adopted on 26.04.2023.	Positive Opinion adopted by consensus on 26.04.2023.
GONAL-f - follitropin alfa - EMEA/H/C/000071/II/0158 Merck Europe B.V., Rapporteur: Johann	Request for supplementary information adopted with a specific timetable.

Lodewijk Hillege, "Update of sections 4.2 and 4.4 of the SmPC in order to align the wording with current clinical practice and to remove Estradiol and follicle number thresholds associated with signs of Ovarian Hyperstimulation Syndrome (OHSS), based on literature and clinical guidelines. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the SmPC." Request for Supplementary Information adopted on 20.04.2023.	
Hepcludex - bulevirtide - EMEA/H/C/004854/II/0019, Orphan Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson, "Update of sections 4.8 and 5.1 of the SmPC in order to update the list of adverse drug reactions (ADRs) and efficacy information based on interim results from study MYR301 listed as a Specific Obligation in the Annex II of the Product Information; this is a Multicenter, Open-label, Randomized Phase III Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients with Chronic Hepatitis Delta. As a result of this variation, the SmPC, Annex II and PL are also updated to reflect the completion of the specific obligation and the CHMP recommendation to grant a marketing authorisation no longer subject to specific obligations. In addition, the MAH took the opportunity to implement editorial changes in the SmPC. The Package Leaflet is updated accordingly. Version 4.0 of the RMP has also been approved (study MYR301 was reclassified from a Category 2 to a Category 3 study)." Opinion adopted on 26.04.2023. Request for Supplementary Information adopted on 15.12.2022.	Positive Opinion adopted by consensus on 26.04.2023. See 9.1
HEPLISAV B - hepatitis B surface antigen - EMEA/H/C/005063/II/0023 Dynavax GmbH, Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to add 'injection site pruritus' to the list of adverse drug reactions (ADRs) with frequency 'uncommon', based on post-marketing surveillance. In addition, the MAH took the opportunity to introduce minor changes to the PI."	Positive Opinion adopted by consensus on 26.04.2023.

Opinion adopted on 26.04.2023.	
Invokana - canagliflozin - EMEA/H/C/002649/II/0062 Janssen-Cilag International N.V., Rapporteur: Martina Weise, "Update of section 4.5 of the SmPC in order to add drug-drug interaction information with lithium, based on a safety review. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Request for Supplementary Information adopted on 14.04.2023.	Request for supplementary information adopted with a specific timetable.
LIVTENCITY - maribavir - EMEA/H/C/005787/II/0002/G, Orphan Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Janet Koenig, "Grouped application consisting of 1) Submission of the final report from study TAK-620-1020. This is a Phase I open-label, randomized, crossover, partially fixed sequence, single-center study to evaluate the pharmacokinetic (PK) profile, safety, and tolerability of maribavir administered to healthy adult subjects of Japanese descent and matched healthy adult, non-Hispanic, Caucasian subjects; 2) Submission of the final report from study TAK 620 1025. This is a Phase I, open-label, randomized, crossover study to evaluate the effect of food on maribavir pharmacokinetics in healthy adult participants." Opinion adopted on 20.04.2023.	Positive Opinion adopted by consensus on 20.04.2023.
LUTATHERA - lutetium (177Lu) oxodotreotide - EMEA/H/C/004123/II/0038, Orphan Advanced Accelerator Applications, Rapporteur: Janet Koenig, "Update of sections 2, 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 5.2, 5.3, 6.2, 6.4, 6.5, 6.6, 11 and 12 of the SmPC to align the Lutathera product information to the latest Core Data Sheet (CDS) version 2.0 (changes to the CDS based on data from the Lutathera existing dossier, current medical practice and new literature). Annex IIIA and the package leaflet are updated accordingly. In addition, additional corrections and changes are made throughout the product information (PI) to comply with the latest QRD template and to improve the language." Opinion adopted on 20.04.2023.	Positive Opinion adopted by consensus on 20.04.2023.

Request for Supplementary Information adopted on 01.12.2022.	
Olumiant - baricitinib - EMEA/H/C/004085/II/0038 Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC to update efficacy information following the CHMP assessment of procedure R/0025 based on final results from study I4V-MC-JADY (JADY; RA BEYOND); This is a long-term extension study: a Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis." Request for Supplementary Information adopted on 20.04.2023.	Request for supplementary information adopted with a specific timetable.
Perjeta - pertuzumab - EMEA/H/C/002547/II/0066 Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, "To update sections 4.8 and 5.1 to reflect updated overall survival data and cardiac safety data, based on interim results from study BO25126 (APHINITY): A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. In addition, the MAH took the opportunity to update the ATC code in the SmPC. Furthermore, the MAH has introduced editorial changes and updated the list of local representatives in the package leaflet." Opinion adopted on 26.04.2023.	Positive Opinion adopted by consensus on 26.04.2023.
Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0043, Orphan EUSA Pharma (Netherlands) B.V., Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.1, 4.2 and 5.1 of the SmPC based on final results from study APN311-202V3 listed as a Specific Obligation in the Annex II of the Product Information. This is a Phase I/II dose schedule finding study of Ch14.18/CHO continuous infusion combined with subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma. In addition, the MAH took the opportunity to update Annex II section E. The Package Leaflet	Request for supplementary information adopted with a specific timetable.

is updated accordingly." Request for Supplementary Information adopted on 26.04.2023, 15.09.2022.	
Qutenza - capsaicin - EMEA/H/C/000909/II/0057 Grunenthal GmbH, Rapporteur: Bruno Sepodes, "Update of sections 4.4 and 4.8 of the SmPC in order to add `Third Degree Burn´ to the list of adverse drug reactions (ADRs) with frequency not known, based on a validated safety signal and post-marketing data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the Package Leaflet." Opinion adopted on 26.04.2023. Request for Supplementary Information adopted on 23.02.2023.	Positive Opinion adopted by consensus on 26.04.2023.
Saphnelo - anifrolumab - EMEA/H/C/004975/II/0007 AstraZeneca AB, Rapporteur: Outi Mäki-Ikola, "Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC based on final results from study D3461C00009 listed as an additional pharmacovigilance activity in the RMP; this is a multicentre, randomised, double-blind, placebo-controlled Phase III extension study to characterise the long-term safety and tolerability of anifrolumab in adult subjects with active systemic lupus erythematosus. In addition, the MAH took the opportunity to implement minor changes to sections 4.2 and 6.6 of the SmPC and to the Package Leaflet." Request for Supplementary Information adopted on 14.04.2023.	Request for supplementary information adopted with a specific timetable.
Segluromet - ertugliflozin / metformin hydrochloride - EMEA/H/C/004314/II/0017 Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder, "To include significant changes to sections 4.4 and 4.8 of the SmPC and section 4 of the Package Leaflet for the medicinal product Segluromet, containing the active substances Ertugliflozin L-pyroglutamic acid and Metformin hydrochloride, regarding the risk for vitamin B12 deficiency. The topic was assessed as part of mutual recognition procedures (FR/H/0181/001-3) for the mono-component containing metformin product (Glucophage). The current proposed	Positive Opinion adopted by consensus on 14.04.2023.

update of the product information for ertugliflozin/metformin combination product (Segluromet) is the same as for the mono-component product containing metformin. In addition, the MAH proposed minor editorial changes to the PI. The proposed update of the PI for the medicinal product Segluromet, containing the active substances Ertugliflozin L-pyroglutamic acid and Metformin hydrochloride." Opinion adopted on 14.04.2023. Request for Supplementary Information adopted on 09.02.2023.	
Simponi - golimumab - EMEA/H/C/000992/II/0109 Janssen Biologics B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Update of the Package Leaflet in order to update the Instructions for Use (IFU) for the pre-filled pen." Request for Supplementary Information adopted on 26.04.2023, 26.01.2023.	Request for supplementary information adopted with a specific timetable.
Tecovirimat SIGA - tecovirimat - EMEA/H/C/005248/II/0005 SIGA Technologies Netherlands B.V., Rapporteur: Jayne Crowe, "Update of section 4.2 of the SmPC in order to introduce a new posology regimen for those with a body weight of 120 kg and above based on final results from study SIGA-246-022 and study report 865, which is a PopPK modelling and simulation report. Study SIGA-246-022 is a multiple-dose, open-label, safety, tolerability, and pharmacokinetic study of tecovirimat in adults weighing more than 120 kg. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Opinion adopted on 26.04.2023.	Positive Opinion adopted by consensus on 26.04.2023.
Twynsta - telmisartan / amlodipine - EMEA/H/C/001224/II/0046/G Boehringer Ingelheim International GmbH, Rapporteur: Martina Weise, "C.I.4: Update of section 4.8 of the SmPC in order to add 'hyponatraemia' to the list of adverse drug reactions (ADRs) with frequency 'rare'; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI,	Positive Opinion adopted by consensus on 26.04.2023.

update the list of local representatives in the Package Leaflet and bring the PI in line with the latest QRD template version 10.3. C.I.z: Update of section 4.9 of the SmPC in order to add the risk of non-cardiogenic pulmonary oedema for amlodipine in case of overdose; the Package Leaflet is updated accordingly." Opinion adopted on 26.04.2023.	
Vargatef - nintedanib - EMEA/H/C/002569/II/0047/G Boehringer Ingelheim International GmbH, Rapporteur: Aaron Sosa Mejia, "Grouped application containing: C.I.4: Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to update information regarding the paediatric population based on results from study 1199-0337; this is a double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib on top of standard of care for 24 weeks, followed by open label treatment with nintedanib of variable duration, in children and adolescents (6 to 17 year-old) with clinically significant fibrosing interstitial lung disease. The Package Leaflet is updated accordingly. C.I.4: Update of sections 4.2 and 5.2 of the SmPC in order to improve the recommendation for the administration of nintedanib based on food compatibility data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to introduce minor editorial changes to the PI." Request for Supplementary Information adopted on 26.04.2023, 26.01.2023.	Request for supplementary information adopted with a specific timetable.
Vokanamet - canagliflozin / metformin - EMEA/H/C/002656/II/0067/G Janssen-Cilag International N.V., Rapporteur: Martina Weise, "C.I.4: Update of section 4.5 of the SmPC in order to add drug-drug interaction information with lithium, based on a safety review. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4: Update of section 4.8 of the SmPC in order to update the frequency for 'vitamin B12 deficiency' in the list of adverse drug reactions	Request for supplementary information adopted with a specific timetable.

(ADRs) to 'common', based on a safety review. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 14.04.2023.	
Yselty - linzagolix choline - EMEA/H/C/005442/II/0005 Theramex Ireland Limited, Rapporteur: Finbarr Leacy, "Submission of the final report from study 22-OBE2109-001. This is a Phase I, open-label, single-dose, single-sequence, crossover drug-drug interaction study designed to evaluate the effect of linzagolix on the PK of the OATP1B1 substrate pitavastatin in healthy female subjects." Opinion adopted on 14.04.2023.	Positive Opinion adopted by consensus on 14.04.2023.
Zejula - niraparib - EMEA/H/C/004249/II/0037, Orphan GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang, "Update of sections 4.2 and 5.2 of the SmPC in order to update recommendations regarding food intake and information on absorption based on results from food effect study 3000-01-004 Stage 3. The package leaflet has been updated accordingly. Furthermore, minor corrections have been made to the product information to reflect that film-coated tablets are provided in blisters. Annex A has been revised accordingly." Opinion adopted on 26.04.2023. Request for Supplementary Information adopted on 15.12.2022.	Positive Opinion adopted by consensus on 26.04.2023.
ZYNRELEF - bupivacaine / meloxicam - EMEA/H/C/005205/II/0011 Heron Therapeutics, B.V., Rapporteur: Alexandre Moreau, "C.I.4. To update SmPC section 4.2 and package leaflet to provide more detailed advice for health care professionals (HCPs) on suturing, especially relating to monofilament sutures and Zynrelef." Opinion adopted on 20.04.2023.	Positive Opinion adopted by consensus on 20.04.2023.
WS2321 CONTROLOC Control- EMEA/H/C/001097/WS2321/0040 PANTOZOL Control- EMEA/H/C/001013/WS2321/0042 SOMAC Control- EMEA/H/C/001098/WS2321/0041 Takeda GmbH, Lead Rapporteur: Larisa	Positive Opinion adopted by consensus on 26.04.2023.

Gorobets, "Update of sections 4.4 in order to add a warning on "Severe Cutaneous Adverse Reactions (SCARs)" based on post-marketing experience. In addition, the MAH proposes to update section 4.5 of the SmPC to introduce information regarding Drug-Laboratory Interactions. The Package Leaflet was updated accordingly. Furthermore, the MAH took the opportunity to implement editorial changes and to update the list of local representatives in the Package Leaflet." Opinion adopted on 26.04.2023. Request for Supplementary Information adopted on 23.02.2023, 24.11.2022, 06.10.2022.	
WS2415 **Vfend-EMEA/H/C/000387/WS2415/0148** Pfizer Europe MA EEIG, Lead Rapporteur: Johann Lodewijk Hillege, "Update of section 4.4 of the SmPC to include increased risk of skin toxicity with concomitant use of voriconazole and methotrexate and potentially other drugs associated with ultraviolet (UV) reactivation to the current warning on photosensitivity skin reactions, based on post-marketing data and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to sections 4.4 and 4.5 of the SmPC." Request for Supplementary Information adopted on 26.04.2023.	Request for supplementary information adopted with a specific timetable.
WS2442 **Exelon-EMEA/H/C/000169/WS2442/0143** **Prometax-EMEA/H/C/000255/WS2442/0144** Novartis Europharm Limited, Lead Rapporteur: Alexandre Moreau, "Update of sections 4.4 and 4.5 of the SmPC in order to strengthen the existing warning on QT prolongation based on post-marketing data and literature; the Package Leaflet is updated accordingly." Opinion adopted on 14.04.2023.	Positive Opinion adopted by consensus on 14.04.2023.
WS2450/G **Glyxambi-EMEA/H/C/003833/WS2450/0051/G** **Synjardy-EMEA/H/C/003770/WS2450/0070/G** Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege, "C.I.4: Update of sections 4.2 and 4.4 of the SmPC in	Request for supplementary information adopted with a specific timetable.

order to modify administration instructions to the elderly, amend an existing warning for the elderly and remove the warning for 'Cardiac Failure' in order to align with the Jardiance Product Information; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.z: Update of section 4.4 of the SmPC in order to introduce a rewording related to use in patients with type 1 diabetes in order to align with the Jardiance Product Information; the Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 26.04.2023.	

B.5.3. CHMP-PRAC assessed procedures

AUBAGIO - teriflunomide - EMEA/H/C/002514/II/0042 Sanofi Winthrop Industrie, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "Submission of the final report of the open-label extension period for study EFC11759, listed as a category 3 study in the RMP. This is a two-year, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate efficacy, safety, tolerability and pharmacokinetics of teriflunomide administered orally once daily in paediatric patients with relapsing forms of multiple sclerosis (MS) followed by an open-label extension. The RMP version 8.1 has also been submitted." Opinion adopted on 14.04.2023. Request for Supplementary Information adopted on 16.03.2023.	Positive Opinion adopted by consensus on 14.04.2023.
AYVAKYT - avapritinib - EMEA/H/C/005208/II/0022, Orphan Blueprint Medicines (Netherlands) B.V., Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2 and 5.2 of the SmPC in order to change posology recommendations and to update pharmacokinetic information for use in patients with severe hepatic impairment based on the final results from study BLU-285-0107 listed as a category 3 study in the RMP; this is a phase 1, open-label, single-dose study to investigate the influence of severe hepatic impairment on the pharmacokinetics of	Positive Opinion adopted by consensus on 26.04.2023.

avapritinib. The package leaflet is updated accordingly. The RMP version 3.0 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3." Opinion adopted on 26.04.2023. Request for Supplementary Information adopted on 23.02.2023.	
Brukinsa - zanubrutinib - EMEA/H/C/004978/II/0009 BeiGene Ireland Ltd, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Menno van der Elst, "Submission of the final report from study BGB-3111-113 - A Drug-Drug Interaction Study of Zanubrutinib with Moderate and Strong CYP3A Inhibitors in Patients With B-Cell Malignancies, listed as a category 3 study in the RMP. The RMP version 3.0 has also been submitted." Request for Supplementary Information adopted on 14.04.2023.	Request for supplementary information adopted with a specific timetable.
GIVLAARI - givosiran - EMEA/H/C/004775/II/0011/G, Orphan Alnylam Netherlands B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "Update of section 5.3 of the SmPC based on final results from study AS1-GLP18-007 listed as a category 3 study in the RMP; This is a 104-week Subcutaneous Injection Carcinogenicity Study in Sprague Dawley Rats. Update of section 5.3 of the SmPC based on final results from study AS1-GLP18-004; This is a 26-week Subcutaneous Injection Carcinogenicity Study in TgRasH2 Mice. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 14.04.2023, 12.01.2023, 29.09.2022.	Request for supplementary information adopted with a specific timetable.
Imnovid - pomalidomide - EMEA/H/C/002682/II/0047, Orphan Bristol-Myers Squibb Pharma EEIG, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Monica Martinez Redondo, "Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern	Request for supplementary information adopted with a specific timetable.

of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The updated RMP version 16 was provided." Request for Supplementary Information adopted on 14.04.2023, 09.02.2023, 27.10.2022.	
Kisplyx - lenvatinib - EMEA/H/C/004224/II/0052 Eisai GmbH, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: David Olsen, "Update of section 4.8 of the SmPC based on pooled safety data including results of study 307, an ongoing, multicentre, randomised, open-label study that is being conducted to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib as first-line (1L) treatment in adults with advanced renal cell carcinoma (RCC). The provision of the CSR addresses the post-authorisation measure MEA/FSR 009.3. The Package Leaflet is updated accordingly. An updated RMP version 15.0 has been submitted." Opinion adopted on 14.04.2023. Request for Supplementary Information adopted on 09.02.2023, 29.09.2022.	Positive Opinion adopted by consensus on 14.04.2023.
Mayzent - siponimod - EMEA/H/C/004712/II/0020 Novartis Europharm Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Maria del Pilar Rayon, "Update of sections 4.4 and 4.8 of the SmPC in order to add "Progressive multifocal leukoencephalopathy (PML)" to the list of adverse drug reactions (ADRs) with frequency "not know" based on post-marketing data. The Annex II (Physician's Checklist), and Package Leaflet are updated accordingly. The RMP version 6.0 has also been submitted. In addition, the MAH took the opportunity to update the text regarding herpes viral infection in the Package Leaflet in alignment with the currently approved SmPC." Request for Supplementary Information adopted on 14.04.2023.	Request for supplementary information adopted with a specific timetable.

Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0094 Sanofi B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault, "Update of section 4.2 of the SmPC in order to add home infusion upon request by PRAC following the assessment of PSUSA/00000086/202109 I based on a cumulative search of the MAH Global Pharmacovigilance database and literature. The Package Leaflet and Annex II are updated accordingly. The RMP version 10.0 has also been submitted." Request for Supplementary Information adopted on 26.04.2023.	Request for supplementary information adopted with a specific timetable.
Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0095 Sanofi B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault, "Update of sections 4.4 and 5.2 of the SmPC in order to update a warning on immunogenicity. The RMP version 10.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Request for Supplementary Information adopted on 14.04.2023.	Request for supplementary information adopted with a specific timetable.
Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0033 AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2, 5.1 and 5.2 of the SmPC and the package leaflet based on results from study PK/PD study listed as a specific obligation in the Annex II in order to fulfil SOB 001 and SOB 003; this is a PK and PK/PD Analysis of Intravenously Administered Andexanet after dosing to steady state with a factor Xa inhibitor, rivaroxaban or apixaban, in healthy subjects and patients who have acute major bleeding. In addition, the MAH took the opportunity to implement editorial changes in Annex II of the SmPC. The RMP version 3.0 has also been submitted." Opinion adopted on 26.04.2023. Request for Supplementary Information adopted on 26.01.2023, 13.10.2022.	Positive Opinion adopted by consensus on 26.04.2023. See 9.1
Rekovelle - follitropin delta - EMEA/H/C/003994/II/0037/G Ferring Pharmaceuticals A/S, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der	Request for supplementary information adopted with a specific timetable.

Elst, "Grouped application comprising two type II variations as follows: - Update of sections 4.1, 4.2, 4.4, 4.5 and 5.1 of the SmPC to update the safety information following final results from study 000304 (BEYOND). This is a randomised, controlled, open label, parallel group, multicentre trial comparing the efficacy and safety of individualised FE 999049 (follitropin delta) dosing, using a long GnRH agonist protocol and a GnRH antagonist protocol in women undergoing controlled ovarian stimulation. - Update of section 4.8 of the SmPC, including the tabulation of adverse drug reactions based on pooled safety data from studies ESTHER-1, ESTHER-2, 000273, 000145, BEYOND and RAINBOW. The updated RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 26.04.2023.	
Revlimid - lenalidomide - EMEA/H/C/000717/II/0123 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The MAH is also taking the opportunity to update the RMP with PASS Protocol milestones. The updated RMP version 38 was provided." Request for Supplementary Information adopted on 14.04.2023, 09.02.2023, 27.10.2022.	Request for supplementary information adopted with a specific timetable.
Stelara - ustekinumab -	Positive Opinion adopted by consensus on

EMEA/H/C/000958/II/0096 Janssen-Cilag International N.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald, "Update of section 5.1 of the SmPC in order to update information with the 4-year clinical data in patients with ulcerative colitis based on the final report from study CNTO1275UCO3001 listed as a category 3 study in the RMP; this is a phase 3, randomised, double blind, placebo-controlled, parallel-group, multicentre study to evaluate the safety and efficacy of ustekinumab induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis. The RMP version 24.1 has also been updated. In addition, the MAH took the opportunity to introduce a correction to the PI." Opinion adopted on 26.04.2023. Request for Supplementary Information adopted on 26.01.2023.	26.04.2023.
Tecentriq - atezolizumab - EMEA/H/C/004143/II/0077/G Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Inês Ribeiro-Vaz, "Grouped application comprising two type II variations as follows: - Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to add dose modification advice and new warning for two new important identified risks of immune-mediated myelitis and immune-mediated facial paresis and to add facial paresis and myelitis to the list of adverse drug reactions (ADRs) with frequency Rare following a safety signal based on the cumulative review of the MAH safety database and literature search. - Update of section 4.8 of the SmPC in order to add dry mouth to the list of adverse drug reactions (ADRs) with frequency Common, based on the results from study WO39210 (IMmotion010), a multicenter, randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of atezolizumab versus placebo in patients with renal cell carcinoma (RCC) who are at high risk of disease recurrence following resection. The Annex II and Package Leaflet are updated accordingly. The RMP version 26.0 has also been submitted. In addition, the MAH took the opportunity to	Positive Opinion adopted by consensus on 26.04.2023.

introduce editorial changes to the SmPC and to update the list of local representatives in the Package Leaflet." Opinion adopted on 26.04.2023.	
Thalidomide BMS - thalidomide - EMEA/H/C/000823/II/0076 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The MAH is also taking the opportunity to update the RMP with PASS Protocol milestones, and to make some editorial changes in the labelling. The updated RMP version 20 was provided." Request for Supplementary Information adopted on 14.04.2023, 09.02.2023, 27.10.2022.	Request for supplementary information adopted with a specific timetable.
WS2421 **Edistride-** **EMEA/H/C/004161/WS2421/0059** **Forxiga-** **EMEA/H/C/002322/WS2421/0080** AstraZeneca AB, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Mari Thorn, "Submission of final results from non-clinical mechanistic model studies listed as a category 3 PASS in the RMP. These are non-clinical studies aiming to further investigate underlying mechanisms of diabetes ketoacidosis (DKA) in association with dapagliflozin. The RMP version 29 has also been submitted." Opinion adopted on 14.04.2023.	Positive Opinion adopted by consensus on 14.04.2023.

B.5.4. PRAC assessed procedures

PRAC Led **Arixtra - fondaparinux sodium -**	Request for supplementary information adopted with a specific timetable.

EMEA/H/C/000403/II/0087 Mylan Ire Healthcare Limited, PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "To update section 4.8 of the SmPC to update the ADR table following the assessment of PSUSA (EMEA/H/C/PSUSA/00001467/202112). The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 14.04.2023.	
PRAC Led **Fintepla - fenfluramine - EMEA/H/C/003933/II/0017, Orphan** UCB Pharma SA, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of an updated RMP version 2.10 in order to implement a targeted follow-up questionnaire (FUQ) to further improve the collection of follow-up information on cases of vascular heart disease (VHD) and pulmonary arterial hypertension (PAH) suggested by PRAC following the assessment of procedure EMEA/H/C/PSUSA/00010907/202112." Request for Supplementary Information adopted on 14.04.2023, 12.01.2023.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Kengrexal - cangrelor - EMEA/H/C/003773/II/0031** Chiesi Farmaceutici S.p.A., PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando Genazzani, "Submission of the final report from study ARCANGELO (itAlian pRospective study on CANGrELOr), listed as a category 3 study in the RMP. This is a multicentre observational, prospective cohort study including patients with acute coronary syndromes undergoing percutaneous coronary intervention who receive cangrelor i.v. transitioning to either clopidogrel, prasugrel or ticagrelor per os. The primary objective is to assess the safety of cangrelor in a real-world setting, when administered in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI). The safety of cangrelor is based on the incidence of any haemorrhage at 30 days post-PCI. The RMP version 5.1 has also been submitted." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 14.04.2023.	
PRAC Led **Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0092** Sanofi B.V., PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "Update of sections 4.6 and 5.3 of the SmPC in order to update information on pregnancy, lactation and fertility following the request by PRAC in the AR for MEA/024.17 and MEA/025.17 and in PSUSA/00000086/202109; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Opinion adopted on 14.04.2023. Request for Supplementary Information adopted on 01.12.2022.	Positive Opinion adopted by consensus on 14.04.2023.
PRAC Led **NutropinAq - somatropin - EMEA/H/C/000315/II/0077** Ipsen Pharma, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Submission of an updated RMP version 4.0 in order to remove some of the safety concerns in compliance with GVP Module V Revision 2. In addition, the MAH took the opportunity to add data from final clinical study report of International Cooperative Growth Study (iNCGS) registry (non-interventional study) and exposure and safety information." Request for Supplementary Information adopted on 14.04.2023, 12.01.2023.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Stocrin - efavirenz - EMEA/H/C/000250/II/0130** Merck Sharp & Dohme B.V., Duplicate, Duplicate of Sustiva, PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "Submission of an updated RMP version 9.0 in accordance with the new template and thereby to remove safety concerns." Opinion adopted on 14.04.2023. Request for Supplementary Information adopted on 12.01.2023.	Positive Opinion adopted by consensus on 14.04.2023.
PRAC Led **Synagis - palivizumab - EMEA/H/C/000257/II/0131**	Positive Opinion adopted by consensus on 14.04.2023.

AstraZeneca AB, PRAC Rapporteur: Marie Louise Schougaard Christiansen, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Submission of an updated RMP in order to remove from the list of safety concerns "Anaphylaxis, Anaphylactic shock, and Hypersensitivity" and "Medication error of mixing lyophilised and liquid palivizumab before injection". In addition, the MAH took the opportunity to apply the revised template. RMP version 2.3 is approved with this procedure." Opinion adopted on 14.04.2023. Request for Supplementary Information adopted on 16.03.2023, 01.12.2022.	
PRAC Led **Tecovirimat SIGA - tecovirimat - EMEA/H/C/005248/II/0006** SIGA Technologies Netherlands B.V., PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of substantial updates to the protocol of study SIGA-246-021 listed as a specific obligation in the Annex II of the Product Information in order to reflect the transfer of sponsorship from SIGA Technologies, Inc. to the NIH Division of Microbiology and Infection Disease protocol. This is a phase 4, observational field study to evaluate safety and clinical benefit in tecovirimat-treated patients following exposure to variola virus and clinical diagnosis of smallpox disease. The Annex II and the RMP submitted version 1.2 are updated accordingly." Request for Supplementary Information adopted on 14.04.2023.	Request for supplementary information adopted with a specific timetable.
PRAC Led **TOBI Podhaler - tobramycin - EMEA/H/C/002155/II/0053, Orphan** Viatris Healthcare Limited, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 8.0 following the request by PRAC in the AR for PSUSA/00009315/202106 in order to update it based on the guidance provided in the GVP and to remove the safety concerns as well as to reflect the finalisation of study CTBM100C2407 and the transfer of ownership." Opinion adopted on 14.04.2023. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 14.04.2023.

on 01.12.2022.	
PRAC Led **VPRIV - velaglucerase alfa - EMEA/H/C/001249/II/0061** Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of an updated RMP version 12 in order to remove certain risks from the list of safety concerns." Request for Supplementary Information adopted on 14.04.2023, 09.02.2023.	Request for supplementary information adopted with a specific timetable.
PRAC Led **WS2402** **Advagraf- EMEA/H/C/000712/WS2402/0069** **Modigraf- EMEA/H/C/000954/WS2402/0045** Astellas Pharma Europe B.V., Lead PRAC Rapporteur: Eamon O Murchu, PRAC-CHMP liaison: Jayne Crowe, "C.I.11.z - To update the EU Risk Management Plan with the new TPRI final study submission milestone, related to procedure EMEA/H/C/000712/MEA030 and EMEA/H/C/000954/MEA022 (Study F506-PV-0001)." Opinion adopted on 26.04.2023. Request for Supplementary Information adopted on 16.03.2023.	Positive Opinion adopted by consensus on 26.04.2023.

B.5.5. CHMP-CAT assessed procedures

Abecma - idecabtagene vicleucel - EMEA/H/C/004662/II/0027, Orphan, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Opinion adopted on 26.04.2023, 21.04.2023. Request for Supplementary Information adopted on 24.03.2023.	Positive Opinion adopted by consensus on 26.04.2023.
Alofisel - darvadstrocel - EMEA/H/C/004258/II/0045/G, Orphan, ATMP Takeda Pharma A/S, Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder Opinion adopted on 26.04.2023, 21.04.2023.	Positive Opinion adopted by consensus on 26.04.2023.
ROCTAVIAN - valoctocogene roxaparvovec - EMEA/H/C/005830/II/0004/G, Orphan,	Positive Opinion adopted by consensus on 26.04.2023.

ATMP BioMarin International Limited, Rapporteur: Violaine Closson Carella, CHMP Coordinator: Jean-Michel Race Opinion adopted on 26.04.2023, 21.04.2023.	

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

PRAC Led **Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0059, ATMP** Amgen Europe B.V, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of an updated RMP version 10 in order to update and reclassify identified risk of 'Disseminated herpetic infection' based on the cumulative assessment of literature review and MAH Global Safety Database and to remove studies 20180062 and 20180099 from Planned and Ongoing Studies from the list of Pharmacovigilance Plan studies in the Annex II." Opinion adopted on 26.04.2023, 21.04.2023. Request for Supplementary Information adopted on 20.01.2023.	Positive Opinion adopted by consensus on 26.04.2023.

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2372/G **Suboxone-EMEA/H/C/000697/WS2372/0056/G** Indivior Europe Limited, Lead Rapporteur: Janet Koenig Opinion adopted on 20.04.2023.	Positive Opinion adopted by consensus on 20.04.2023.
WS2414/G **Mircera-EMEA/H/C/000739/WS2414/0093/G** **NeoRecormon-EMEA/H/C/000116/WS2414/0119/G** Roche Registration GmbH, Lead Rapporteur: Martina Weise Opinion adopted on 14.04.2023.	Positive Opinion adopted by consensus on 14.04.2023.
WS2433 **Hexacima-EMEA/H/C/002702/WS2433/0145**	Positive Opinion adopted by consensus on 26.04.2023.

Hexyon- **EMEA/H/C/002796/WS2433/0149** Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus	
WS2447/G **Fluenz Tetra-** **EMEA/H/C/002617/WS2447/0126/G** **Pandemic influenza vaccine H5N1 AstraZeneca-** **EMEA/H/C/003963/WS2447/0061/G** AstraZeneca AB, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 14.04.2023.	Positive Opinion adopted by consensus on 14.04.2023.
WS2455/G **Ongentys-** **EMEA/H/C/002790/WS2455/0058/G** **Ontilyv-** **EMEA/H/C/005782/WS2455/0013/G** Bial - Portela & Cª, S.A., Lead Rapporteur: Martina Weise Opinion adopted on 26.04.2023.	Positive Opinion adopted by consensus on 26.04.2023.

B.5.9. Information on withdrawn type II variation / WS procedure

Supemtek - influenza quadrivalent vaccine (rDNA) - EMEA/H/C/005159/II/0009 Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus, "Update of section 5.1 of the SmPC in order to update the efficacy information based on final results from study VAP00003 listed as a category 3 study in the RMP; this is a phase 4, multi-center, modified-cluster randomized study to assess the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine in adults. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Request for Supplementary Information adopted on 15.12.2022.	The MAH withdrew the application on 30.03.2023
LUTATHERA - lutetium (177Lu) oxodotreotide - EMEA/H/C/004123/II/0039, Orphan Advanced Accelerator Applications, Rapporteur: Janet Koenig Request for Supplementary Information adopted on 26.01.2023.	The MAH withdrew the application on 20.04.2023

WS2448 **Filgrastim Hexal-** **EMEA/H/C/000918/WS2448/0069** **Zarzio-EMEA/H/C/000917/WS2448/0070** Sandoz GmbH, Lead Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 14.04.2023. Withdrawal request submitted on 21.04.2023.	The MAH withdrew the procedure on 21.04.2023.

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

in vitro diagnostic medical device - **EMEA/H/D/006232** to detect rearrangements involving the ALK gene via fluorescence

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

Adtralza - tralokinumab - **EMEA/H/C/005255/X/0007** LEO Pharma A/S, Rapporteur: Jayne Crowe, PRAC Rapporteur: Kimmo Jaakkola, "Extension application to add a new strength of 300 mg (150 mg/ml) tralokinumab solution for injection in pre-filled pen for subcutaneous administration. The RMP (version 1.1) is updated accordingly." List of Questions adopted on 30.03.2023.
dantrolene sodium, hemiheptahydrate - **EMEA/H/C/006009, Orphan** Norgine B.V., treatment of malignant hyperthermia (including suspected cases) List of Questions adopted on 10.11.2022.
in vitro diagnostic medical device - **EMEA/H/D/006233** To determine HER2 (Human Epidermal Growth Factor Receptor 2) oncoprotein status

Request for Supplementary Information adopted on 30.03.2023.

latanoprost - EMEA/H/C/005933
Reduction of elevated intraocular pressure (IOP)
List of Questions adopted on 26.01.2023.

Erleada - apalutamide - EMEA/H/C/004452/X/0028/G
Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Tiphaine Vaillant, "Extension application to add a new strength (240 mg) film-coated tablets grouped with the IB variation (C.I.z).
The RMP (version 6.1) has also been submitted.
C.I.z (IB): to align the SmPC/PL for Erleada 60 mg with the SmPC/PL proposed for the registration of the new Erleada film-coated tablet strength, 240 mg.
The PL for Erleada 60 mg is proposed to be updated to ensure consistency.
In addition, few minor revisions are proposed to the SmPC for Erleada 60 mg, to align the SmPC proposed for the 240 mg strength:
- SmPC sections 5.1 and 5.2: Orthographic corrections
- SmPC section 6.5: Further details on the description of the current packaging have been added, this change does not result from a change to the container.
- SmPC section 6.6: The title of the section has been aligned with QRD template."
List of Questions adopted on 30.03.2023.

fezolinetant - EMEA/H/C/005851
treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause
List of Questions adopted on 26.01.2023.

Xolair - omalizumab - EMEA/H/C/000606/X/0115/G
Novartis Europharm Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn"Extension application to add a new strength of 300 mg (150 mg/ml) for Xolair solution for injection grouped with quality type II, IB and IAIN variations. The RMP (version 17.0) is updated in accordance.
List of Questions adopted on 15.12.2022.

zilucoplan - EMEA/H/C/005450, Orphan
UCB Pharma S.A., treatment of generalised myasthenia gravis in adults

List of Questions adopted on 26.01.2023.

B.6.4. Annual Re-assessments: timetables for adoption

Chenodeoxycholic acid Leadiant - chenodeoxycholic acid - EMEA/H/C/004061/S/0022, Orphan
Leadiant GmbH, Rapporteur: Anastasia Mountaki, PRAC Rapporteur: Adam Przybylkowski

DECTOVA - zanamivir - EMEA/H/C/004102/S/0016
GlaxoSmithKline Trading Services Limited, Rapporteur: Ingrid Wang, PRAC Rapporteur: Ulla Wändel Liminga

Elaprase - idursulfase - EMEA/H/C/000700/S/0111
Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan

Firdapse - amifampridine - EMEA/H/C/001032/S/0075
SERB SA, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Adakveo - crizanlizumab - EMEA/H/C/004874/R/0014, Orphan
Novartis Europharm Limited, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jo Robays

Besremi - ropeginterferon alfa-2b - EMEA/H/C/004128/R/0031
AOP Orphan Pharmaceuticals GmbH, Rapporteur: Janet Koenig, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Inês Ribeiro-Vaz

Bevespi Aerosphere - glycopyrronium / formoterol fumarate dihydrate - EMEA/H/C/004245/R/0017
AstraZeneca AB, Rapporteur: Kristina Dunder, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Jan Neuhauser

Erleada - apalutamide -

EMEA/H/C/004452/R/0030
Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Elita Poplavska, PRAC Rapporteur: Tiphaine Vaillant

Silodosin Recordati - silodosin - EMEA/H/C/004964/R/0012
Recordati Ireland Ltd, Generic, Generic of Urorec, Rapporteur: Margareta Bego, PRAC Rapporteur: Valentina Di Giovanni

TECFIDERA - dimethyl fumarate - EMEA/H/C/002601/R/0083
Biogen Netherlands B.V., Rapporteur: Martina Weise, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Martin Huber

Vantobra - tobramycin - EMEA/H/C/005086/R/0009
PARI Pharma GmbH, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

ASPAVELI - pegcetacoplan - EMEA/H/C/005553/II/0011, Orphan
Swedish Orphan Biovitrum AB (publ), Rapporteur: Alexandre Moreau, Co-Rapporteur: Selma Arapovic Dzakula, PRAC Rapporteur: Kimmo Jaakkola, "Extension of indication to include treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously treated with a complement inhibitor for ASPAVELI, based on final results from study APL2-308. This is a Phase III, randomized, open-label, comparator-controlled study that enrolled adult patients with PNH who had not been treated with a complement inhibitor. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted."

Beyfortus - nirsevimab - EMEA/H/C/005304/II/0005
AstraZeneca AB, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Kimmo Jaakkola, "Extension of indication to include treatment of children up to 24 months of age

who remain vulnerable to severe Respiratory Syncytial Virus (RSV) disease through their second RSV season for BEYFORTUS, based on interim results from studies D5290C00005 and D5290C00008. Study D5290C00005 (MEDLEY) is a Phase II/III, randomized, double-blind, placebo-controlled study to evaluate the safety of Beyfortus in high-risk children. Study D5290C00008 (MUSIC) is a Phase II, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetics, and occurrence of antidrug antibody for Beyfortus in immunocompromised children ≤ 24 Months of Age. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 2.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."	
Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/004993/II/0043 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "Extension of indication to include adults 50 years of age and older for Fluad Tetra, based on final results from study V118_23; this is a phase 3, randomized, observer-blind, controlled, multicenter, clinical study to evaluate immunogenicity and safety of an MF59-adjuvanted quadrivalent subunit inactivated influenza vaccine in comparison with a licensed quadrivalent influenza vaccine, in adults 50 to 64 years of age. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Labelling and Package Leaflet are updated in accordance. Version 2.9 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI."	
JEMPERLI - dostarlimab - EMEA/H/C/005204/II/0023 GlaxoSmithKline (Ireland) Limited, Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Inês Ribeiro-Vaz, "Extension of indication to include in	

combination with platinum-containing chemotherapy the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy, based on results from study 213361 (RUBY) Part 1, listed as a Specific Obligation in the Annex II; this is a phase 3, randomized, double-blind, multicenter study of dostarlimab (TSR-042) plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced endometrial cancer. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Annex II and Package Leaflet are updated in accordance. Version 3.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI. As part of the application, the MAH is requesting a 1-year extension of the market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
LIVMARLI - maralixibat - EMEA/H/C/005857/II/0003/G, Orphan Mirum Pharmaceuticals International B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Adam Przybylkowski, "Grouped variation consisting of: 1) Extension of indication to include treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients 2 months of age and older for LIVMARLI, based on results from studies MRX-502, LUM001-501, MRX-503, MRX-800 and MRX-801; MRX-502 is an international, multicenter, randomized, double-blind, placebo-controlled, parallel group Phase 3 study that evaluated the efficacy and safety of maralixibat in PFIC participants aged >12 months to <18 years on a proposed dosage of up to 600 µg/kg BID over 6 months. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Annex II are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes.	

2) B.I.b.1.b - type IA ”
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Advate - octocog alfa - EMEA/H/C/000520/II/0120/G
Takeda Manufacturing Austria AG, Rapporteur: Jan Mueller-Berghaus

Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0014/G
Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphy

Azacitidine betapharm - azacitidine - EMEA/H/C/005075/II/0015
betapharm Arzneimittel GmbH, Generic, Generic of Vidaza, Rapporteur: Petr Vrbata

Azacitidine betapharm - azacitidine - EMEA/H/C/005075/II/0016
betapharm Arzneimittel GmbH, Generic, Generic of Vidaza, Rapporteur: Petr Vrbata

COMIRNATY - tozinameran - EMEA/H/C/005735/II/0178
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

Eylea - aflibercept - EMEA/H/C/002392/II/0086
Bayer AG, Rapporteur: Alexandre Moreau

Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0053/G, Orphan
Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia

LIVMARLI - maralixibat - EMEA/H/C/005857/II/0002, Orphan
Mirum Pharmaceuticals International B.V., Rapporteur: Martina Weise

NUVAXOVID - Covid-19 vaccine (recombinant, adjuvanted) - EMEA/H/C/005808/II/0048/G
Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege

Ontruzant - trastuzumab -

EMEA/H/C/004323/II/0046/G
Samsung Bioepis NL B.V., Rapporteur: Karin Janssen van Doorn

Pazenir - paclitaxel - EMEA/H/C/004441/II/0014
ratiopharm GmbH, Generic, Generic of Abraxane, Rapporteur: Daniela Philadelphy

Pluvicto - lutetium (177Lu) vipivotide tetraxetan - EMEA/H/C/005483/II/0003
Novartis Europharm Limited, Rapporteur: Janet Koenig

Spikevax - elasomeran - EMEA/H/C/005791/II/0100/G
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus

Surgiflo Haemostatic Matrix Kit - human thrombin - EMEA/H/D/002301/II/0034/G
Ferrosan Medical Devices A/S, Rapporteur: Jan Mueller-Berghaus

TOBI Podhaler - tobramycin - EMEA/H/C/002155/II/0057/G, Orphan
Viatris Healthcare Limited, Rapporteur: Johann Lodewijk Hillege

Toujeo - insulin glargine - EMEA/H/C/000309/II/0121/G
Sanofi-Aventis Deutschland GmbH, Duplicate, Duplicate of Lantus, Rapporteur: Johann Lodewijk Hillege

TRODELVY - sacituzumab govitecan - EMEA/H/C/005182/II/0023/G
Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus

TRODELVY - sacituzumab govitecan - EMEA/H/C/005182/II/0024/G
Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0119/G
MCM Vaccine B.V., Rapporteur: Christophe Focke

VidPrevtyn Beta - SARS-CoV-2, B.1.351 variant, prefusion Spike delta TM protein,

recombinant - EMEA/H/C/005754/II/0003
Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus

Voxzogo - vosoritide - EMEA/H/C/005475/II/0007, Orphan
BioMarin International Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Zane Neikena

Zinplava - bezlotoxumab - EMEA/H/C/004136/II/0038/G
Merck Sharp & Dohme B.V., Rapporteur: Jan Mueller-Berghaus

WS2479
Hexacima- EMEA/H/C/002702/WS2479/0146
Hexyon- EMEA/H/C/002796/WS2479/0150
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

CABOMETYX - cabozantinib - EMEA/H/C/004163/II/0032
Ipsen Pharma, Rapporteur: Ingrid Wang, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on Vanishing Bile Duct Syndrome (VBDS), to add embolism arterial to the list of adverse drug reactions (ADRs) with frequency Uncommon and to add vanishing bile duct syndrome to the list of adverse drug reactions (ADRs) with frequency Not known based on the cumulative review of the global safety database and literature search. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Dupixent - dupilumab - EMEA/H/C/004390/II/0071
Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC in order to support the longer-term (5-year) safety of dupilumab in adults with moderate-to-severe Atopic Dermatitis (AD) based on final results from study R668-AD-1225 listed as a specific PASS category 3 study in the RMP.
The study R668-AD-1225 was a phase 3, multicenter, open-label extension (OLE) study of

dupilumab in adults with moderate-to-severe atopic dermatitis (AD) who had previously participated in dupilumab clinical trials. The main objective of this study is to assess the long-term safety of dupilumab administered in adult patients with AD."

Dupixent - dupilumab - EMEA/H/C/004390/II/0072

Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update the safety and efficacy information relevant to patients with hand and foot Atopic Dermatitis based on the results from study R668-AD-1924. This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Hand and Foot Dermatitis."

Kanuma - sebelipase alfa - EMEA/H/C/004004/II/0044, Orphan

Alexion Europe SAS, Rapporteur: Karin Janssen van Doorn, "Update of sections 4.2 and 6.6 of the SmPC in order to limit the 1-hour infusion time only to those patients receiving the 1 mg/kg dose and to modify the table for 'recommended infusion volumes' to address the USP endotoxin limit. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Kisqali - ribociclib - EMEA/H/C/004213/II/0041/G

Novartis Europharm Limited, Rapporteur: Filip Josephson, "Grouped application comprising two type II variations as follows:
- Update of section 5.2 of the SmPC in order to update absorption information based on final results from study CLEE011A2117, a Phase I, single center, two-period, two-treatment, open label, randomized crossover study to investigate the absolute bioavailability of a single oral dose of 600 mg of ribociclib relative to an intravenous (i.v.) infusion of 150 mg ribociclib in healthy subjects.
- Update of sections 4.2 and 4.5 of the SmPC in order to update the recommended dose modification when ribociclib is administered in

combination with CYP3A4 inhibitors and update the drug-drug interaction information on substances that may increase ribociclib plasma concentrations based on the updated PBPK modelling.
In addition, the MAH took this opportunity to introduce minor editorial changes to the Package Leaflet."

Koselugo - selumetinib - EMEA/H/C/005244/II/0013, Orphan
AstraZeneca AB, Rapporteur: Alexandre Moreau, "Update of sections 4.2 and 5.2 of the SmPC in order to update the recommended dosage regimen to remove the fasting state and update pharmacokinetic information, based on the final results from study D1346C00015; this is a phase 1, single-arm, sequential study to evaluate the effect of food on the gastrointestinal tolerability and pharmacokinetics of selumetinib after multiple doses in adolescent children with neurofibromatosis type 1 (NF1) related plexiform neurofibromas (PN). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Nexviadyme - avalglucosidase alfa - EMEA/H/C/005501/II/0008
Sanofi B.V., Rapporteur: Christian Gartner, "Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update the list of adverse drug reactions (ADRs) and to update the safety and efficacy information, based on interim results from the open-label extension period of study EFC14028 as well as pooled safety and immunogenicity data. EFC14028 is a phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of avalglucosidase alfa and alglucosidase alfa in treatment naïve patients with late-onset Pompe disease. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Orgovyx - relugolix - EMEA/H/C/005353/II/0012
Accord Healthcare S.L.U., Rapporteur: Johann Lodewijk Hillege, "Update of section 4.5 of the

SmPC based on final results from study MVT-601-9039; this is an In vitro Interaction Study of Relugolix with human OATP2B1 Uptake Transporter."

Paxlovid - nirmatrelvir / ritonavir - EMEA/H/C/005973/II/0040/G

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Grouped application comprising two type II variations as follows:
- Update of section 4.3 of the SmPC in order to add 'Mineralocorticoid receptor antagonists: finerenone' and 'Opioid antagonists: naloxegol' under Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions and to add 'primidone' and 'Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor' under Medicinal products that are potent CYP3A inducers where significantly reduced nirmatrelvir/ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance based on the review of the PI for a number of medicines from different drug classes that are metabolised by CYP3A4 or CYP2D6, transported by P-gp, or induce CYP3A4.
- Update of section 4.5 of the SmPC in order to add drug-drug interaction information with Alpha1-adrenoreceptor antagonist, Analgesics, Antiarrhythmics, Anticoagulants, Anticonvulsants, Anti-HIV, Anti-infectives, β2-agonist (long acting), Calcium channel antagonists, Cardiovascular agents and Migraine medicinal products, to add drug-drug interaction information with Cystic fibrosis transmembrane conductance regulator potentiators, Dipeptidyl peptidase 4 (DPP4) inhibitors, Janus kinase (JAK) inhibitors, Mineralocorticoid receptor antagonists, Muscarinic receptor antagonists, Neuropsychiatric agents and Opioid antagonists and order to remove cross reference to section 4.4 from information regarding coadministration of Paxlovid with Antidepressants based on the review of the PI for a number of medicines from different drug classes that are metabolised by CYP3A4 or CYP2D6, transported by P-gp, or induce CYP3A4."

Paxlovid - nirmatrelvir / ritonavir - EMEA/H/C/005973/II/0042

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy, safety and pharmacokinetic information, based on updated results from studies C4671005 (EPIC-HR), C4671002 (EPIC-SR) and C4671006 (EPIC-PEP) as well as a supplemental report to Pop PK analysis PMAR-EQDD-C467a-DP4-1323, following the reanalysis of data after the removal of data related to four sites from the Paxlovid data analysis."

RINVOQ - upadacitinib - EMEA/H/C/004760/II/0034

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "Submission of the final report from study M13-542, listed as a category 3 study in the RMP. This is a phase 3, randomized, double-blind study comparing upadacitinib (ABT-494) to placebo on stable conventional synthetic disease-modifying anti rheumatic drugs (csDMARDs) in subjects with moderately to severely active rheumatoid arthritis with inadequate response or intolerance to biologic DMARDs (bDMARDs)."

RINVOQ - upadacitinib - EMEA/H/C/004760/II/0035

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "Submission of the final report from study M13-549 listed as a category 3 study in the RMP. This is a Phase III, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs."

Scemblix - asciminib - EMEA/H/C/005605/II/0004/G, Orphan

Novartis Europharm Limited, Rapporteur: Janet Koenig, "Grouped application comprising two type II variations as follows:
- Submission of the final reports from study DMPK-R2200470 (REC). This is an in vitro evaluation of inducibility of OATP1V1, MDR1 and CYP3A4 by asciminib using human hepatocytes.
- Submission of the final report from study

DMPK-R2270399 (REC). This is a physiologically based PK modelling and simulations to characterise the effect of cyclodextrins on the exposure of asciminib."

Spinraza - nusinersen - EMEA/H/C/004312/II/0029, Orphan

Biogen Netherlands B.V., Rapporteur: Bruno Sepodes, "Update of section 5.3 of the SmPC in order to update non-clinical information based on final results from study P058-17-02. This is a 24-month carcinogenicity study when administered by subcutaneous injection in mouse."

TUKYSA - tucatinib - EMEA/H/C/005263/II/0013

Seagen B.V., Rapporteur: Aaron Sosa Mejia, "Submission of the final report from study ONT-380-206 (HER2CLIMB) listed as a PAES in the Annex II of the Product Information. This is a phase 2 randomized, double-blinded, controlled study of tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated unresectable locally advanced or metastatic HER2+ breast carcinoma. The Annex II is updated accordingly."

Xultophy - insulin degludec / liraglutide - EMEA/H/C/002647/II/0049

Novo Nordisk A/S, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add dysgeusia to the list of adverse drug reactions (ADRs) with frequency uncommon based on post-marketing data and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update section 4.9 of the SmPC to update overdose information and to amend Annex A."

Zokinvy - lonafarnib - EMEA/H/C/005271/II/0004, Orphan

EigerBio Europe Limited, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.2, 4.4, 4.5 and 6.6 of the SmPC in order to update drug-drug interaction information based on final results from Drug-Drug Interaction study EIG-LNF-021. This is a phase I, single-center, two period, single sequence, study to assess the effects of lonafarnib autoinhibition following multiple-dose lonafarnib and the effects of a nonspecific CYP2C9 inhibitor on multiple-dose

lonafarnib pharmacokinetics in healthy subjects. The Package Leaflet is updated accordingly.”	
WS2467 **Adrovance-** **EMEA/H/C/000759/WS2467/0051** **FOSAVANCE-** **EMEA/H/C/000619/WS2467/0054** **VANTAVO-** **EMEA/H/C/001180/WS2467/0041** Organon N.V., Lead Rapporteur: Christian Gartner, “Update of sections 4.4 and 4.8 of the SmPC in order to include information on the risk of low-energy fractures in bones other than femur based on post-marketing case reports and the literature. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH the opportunity to update the list of local representatives in the Package Leaflet, to bring the PI in line with the latest QRD template and to introduce editorial changes.”	
WS2489/G **Kinzalmono-** **EMEA/H/C/000211/WS2489/0119/G** **Micardis-** **EMEA/H/C/000209/WS2489/0127/G** **Pritor-** **EMEA/H/C/000210/WS2489/0132/G** Boehringer Ingelheim International GmbH, Lead Rapporteur: Armando Genazzani, “Grouped application consisting of: C.I.4: Update of section 4.8 of the SmPC in order to include “hyponatremia” to the list of adverse drug reactions (ADRs) with frequency “rare”, based on post-marketing data and literature; C.I.z (Type IB unforeseen): Update of section 4.2 of the SmPC to include the possibility of using the combination of telmisartan and amlodipine for lowering blood pressure based on literature; C.I.z (Type IB unforeseen): Update of section 4.7 of the SmPC to replace the terms “dizziness” and “drowsiness” by “syncope” and “vertigo” to align with adverse reactions table in section 4.8 of SmPC. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, bring the PI in line with the	

latest QRD template version 10.3 and to implement editorial changes to the SmPC."

WS2492
Glyxambi-
EMEA/H/C/003833/WS2492/0052
Synjardy-
EMEA/H/C/003770/WS2492/0071
Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege, "Submission of the final report from study PASS 1245-0137 listed as a category 3 study in the RMP. This is a multicentre international randomised parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardiorenal outcomes in patients with chronic kidney disease."

B.6.10. CHMP-PRAC assessed procedures

Enhertu - trastuzumab deruxtecan -
EMEA/H/C/005124/II/0031
Daiichi Sankyo Europe GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Inês Ribeiro-Vaz, "Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update safety, efficacy and pharmacokinetic information based on data from study DS8201-A-U301 and study DS8201-A-U302. Study U301 was a Phase 3, randomized, 2-arm, open-label, multicenter study designed to compare the safety and efficacy of T-DXd vs TPC in HER2-positive, unresectable and/or metastatic BC subjects who were resistant or refractory to T-DM1. Study U302 was a Phase 3, multicenter, randomized, open-label, 2-arm, active-controlled study in subjects with unresectable and/or metastatic HER2-positive (IHC 3+ or ISH-positive) BC previously treated with trastuzumab plus taxane in the advanced/metastatic setting or who had progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab plus taxane. The Package Leaflet and Annex II are updated accordingly. The updated RMP version 4.1 has also been submitted."

Fluenz Tetra - influenza vaccine (live attenuated, nasal) -
EMEA/H/C/002617/II/0130
AstraZeneca AB, Rapporteur: Christophe Focke,

PRAC Rapporteur: Jean-Michel Dogné, "Submission of the final report from study MA-VA-MEDI3250-1116 (A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2 to 17 Years of Age) listed as a category 3 study in the RMP. This was an observational study. The objective of this study was to evaluate the effectiveness of Q/LAIV compared to IIV or no vaccine in community-dwelling subjects 2 to 17 years of age against laboratory-confirmed influenza. The RMP version 11.0 has also been submitted."

Veklury - remdesivir - EMEA/H/C/005622/II/0050

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová, "Update of sections 4.2, 4.4, 4.8 and 5.2 of the SmPC in order to address the safety of remdesivir and its metabolites in patients with hepatic impairment and to update information on hepatic and coagulation laboratory abnormalities based on final results from study GS US 540 9014: "A phase 1 open-label, adaptive, single-dose study to evaluate the pharmacokinetics of remdesivir and its metabolite(s) in subjects with normal hepatic function and hepatic impairment", listed as a category 3 study in the RMP, and on safety data from post-marketing and clinical trials experience.
The Package Leaflet is updated accordingly. The RMP version 5.4 has also been submitted. In addition, the MAH took the opportunity submit Minor Linguistic Amendments (MLA) for Veklury."

XOSPATA - gilteritinib - EMEA/H/C/004752/II/0013, Orphan

Astellas Pharma Europe B.V., Rapporteur: Ingrid Wang, PRAC Rapporteur: Martin Huber, "Update of sections 4.2 and 5.2 in order to update the information on renal impairment based on final results from study 2215-CL-0114, listed as a category 3 study in the RMP. Study 2215-CL-0114 is a phase 1, single-dose, open-label study to investigate the effect of renal impairment on gilteritinib pharmacokinetics, safety and tolerability in 9 participants with severe renal impairment compared to 8 participants with normal renal function.

The RMP version 4.0 has also been submitted.
In addition, the MAH took the opportunity to introduce editorial changes."

B.6.11. PRAC assessed procedures

PRAC Led
CABOMETYX - cabozantinib - EMEA/H/C/004163/II/0033
Ipsen Pharma, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final report from study F-FR-60000-001 (CASSIOPE) listed as a category 3 study in the RMP. This is a prospective, non-imposed and non-interventional study of cabozantinib tablets in adults with advanced renal cell carcinoma (RCC) following prior vascular endothelial growth factor (VEGF)-targeted therapy. The RMP version 7.0 has also been submitted."

PRAC Led
Eurartesim - piperaquine tetraphosphate / artenimol - EMEA/H/C/001199/II/0040/G
Alfasigma S.p.A., PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "C.I.13: Submission of the final report from the effectiveness evaluation survey for Eurartesim (protocol no. 3366) listed as a category 3 study in the RMP. This is a European multi-centre online survey to assess physician understanding of the revised edition of the educational material. Consequential changes to RMP version 16.1 have been implemented.
C.I.11.b: Submission of an updated RMP version 16.1 in order to delete "Severe Malaria" from the Missing Information."

PRAC Led
EXJADE - deferasirox - EMEA/H/C/000670/II/0085
Novartis Europharm Limited, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of an updated RMP version 21.0 in order to include the physician survey CICL670A2429 as a PASS category 3, based on the submission of a draft version of the protocol for the physician survey CICL670A2429. The Annex IID is updated to remove one sentence related to 'surveillance programme' and to introduce a minor correction."

PRAC Led

JCOVDEN - COVID-19 vaccine Janssen (Ad26.COV2.S) - EMEA/H/C/005737/II/0071/G

Janssen-Cilag International N.V., PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Grouped application consisting of:
1) Submission of the final study report of a clinical TTS characterisation study listed as a category 3 study in the RMP. This is a Test Pre- and Post-Vaccination Serum Across All Populations Using Clinical Samples From Ad26-based Company Vaccine Studies Other Than Ad26.COV2.S;
2) Submission of the Addendum to final CSR of the study VAC31518COV2001 listed as a category 3 study in the RMP. This is a randomized, double-blind, placebo-controlled Phase 2a study to evaluate a range of dose levels and vaccination intervals of Ad26.COV2.S in healthy adults aged 18 to 55 years, and adults aged 65 years and older. The RMP version 6.1 has also been submitted."

PRAC Led

JCOVDEN - COVID-19 vaccine Janssen (Ad26.COV2.S) - EMEA/H/C/005737/II/0072/G

Janssen-Cilag International N.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Update of section 4.4 of the SmPC in order to add a new warning on pericarditis and myocarditis and update of section 4.8 of the SmPC to add myocarditis and pericarditis to the list of adverse drug reactions (ADRs) with frequency not known based on post-marketing data and three observational claims databases in US. The Package Leaflet is updated accordingly. The RMP version 6.2 has also been submitted. In addition, the MAH took the opportunity to update the ATC Code as amended by the WHO."

PRAC Led

Nexium Control - esomeprazole - EMEA/H/C/002618/II/0038

GlaxoSmithKline Dungarvan Ltd, PRAC Rapporteur: Rugile Pilviniene, PRAC-CHMP liaison: Vilma Petrikaite, "Submission of an

updated RMP version 2.0 in order to update the list of safety concerns to meet the definition of important risk and missing information provided in GVP Module V Rev. 2”

PRAC Led

Olumiant - baricitinib - EMEA/H/C/004085/II/0039/G

Eli Lilly Nederland B.V., PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, “Submission of the final reports from studies I4V-MC-B016 and I4V-MC-B011 listed as category 3 non-interventional PASS studies in the RMP. B016 is a drug utilisation study for the assessment of off-label use of baricitinib in the paediatric population in the United Kingdom. B011 is a retrospective cohort study to assess the safety of baricitinib compared with other therapies used in the treatment of rheumatoid arthritis in Nordic countries. The RMP version 19.1 has also been submitted.”

PRAC Led

Pradaxa - dabigatran etexilate - EMEA/H/C/000829/II/0144

Boehringer Ingelheim International GmbH, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, “Submission of the final report from the Human Factors Study (007-HFE-009035), listed as a category 3 study in the RMP; this is a non-interventional study to assess the effectiveness of a training video to mitigate potential medication errors during the reconstitution and dosing of the dabigatran etexilate paediatric oral solution.”

PRAC Led

Revlimid - lenalidomide - EMEA/H/C/000717/II/0126

Bristol-Myers Squibb Pharma EEIG, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, “Submission of the final report from study CC-5013-MDS-010 listed as an obligation in the Annex II of the Product Information. This is a prospective non-interventional post-authorisation safety study (PASS), designed as a disease registry of patients with transfusion dependent IPSS low or intermediate-1-risk myelodysplastic syndromes (MDS) and isolated del(5q). Section D of the

Annex II and the RMP (version 39) are updated accordingly."

PRAC Led

Vaxzevria - COVID 19 vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0091

AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, "Submission of the final report from study D8111R00020 listed as a category 3 study in the RMP. This is a systematic literature review for studies evaluating adverse events of Vaxzevria in patients taking immunosuppressant medications and/or with primary immunodeficiency."

PRAC Led

WS2483
Lixiana-EMEA/H/C/002629/WS2483/0045
Roteas-EMEA/H/C/004339/WS2483/0032

Daiichi Sankyo Europe GmbH, Lead PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report from DSE-EDO-04-14-EU (Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients with Non-Valvular Atrial Fibrillation, ETNA-AF Europe), listed as a category 3 study in the RMP (MEA 006). This is a multicentre, prospective, non-interventional, observational PASS. The RMP version 15.1 has also been submitted."

PRAC Led

WS2487
Humalog-EMEA/H/C/000088/WS2487/0199
Liprolog-EMEA/H/C/000393/WS2487/0159

Eli Lilly Nederland B.V., Lead PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "To remove severe hypoglycemia as a result of incorrect or incomplete data provided to a compatible software application which is listed as an important potential risk for the Tempo Pen and all associated risk minimisation measures, following PRAC assessment of F3Z-MC-B030 PASS protocol (EMA/PRAC/781358/2022, 29 September 2022)."

B.6.12. CHMP-CAT assessed procedures

Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0018/G, ATMP
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani

Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0019, ATMP
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani

CARVYKTI - ciltacabtagene autoleucel - EMEA/H/C/005095/II/0016, Orphan, ATMP
Janssen-Cilag International NV, Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0070/G, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2427/G
Silodosin Recordati- EMEA/H/C/004964/WS2427/0011/G
Silodyx- EMEA/H/C/001209/WS2427/0051/G
Urorec- EMEA/H/C/001092/WS2427/0054/G
Recordati Ireland Ltd, Generic, Generic of Urorec, Lead Rapporteur: Margareta Bego

WS2445
Ambirix- EMEA/H/C/000426/WS2445/0127
Cervarix- EMEA/H/C/000721/WS2445/0122
Fendrix-

EMEA/H/C/000550/WS2445/0082
Infanrix hexa-
EMEA/H/C/000296/WS2445/0329
Synflorix-
EMEA/H/C/000973/WS2445/0180
Twinrix Adult-
EMEA/H/C/000112/WS2445/0162
Twinrix Paediatric-
EMEA/H/C/000129/WS2445/0163
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Kristina Dunder

WS2456/G
Infanrix hexa-
EMEA/H/C/000296/WS2456/0328/G
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2458
Juluca-EMEA/H/C/004427/WS2458/0051
Tivicay-EMEA/H/C/002753/WS2458/0087
Triumeq-
EMEA/H/C/002754/WS2458/0112
ViiV Healthcare B.V., Lead Rapporteur: Janet Koenig

WS2466
Fluenz Tetra-
EMEA/H/C/002617/WS2466/0128
Pandemic influenza vaccine H5N1
AstraZeneca-
EMEA/H/C/003963/WS2466/0063
AstraZeneca AB, Lead Rapporteur: Christophe Focke

WS2468/G
Hexacima-
EMEA/H/C/002702/WS2468/0148/G
Hexyon-
EMEA/H/C/002796/WS2468/0152/G
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

WS2469
Hexacima-
EMEA/H/C/002702/WS2469/0147
Hexyon-
EMEA/H/C/002796/WS2469/0151
MenQuadfi-
EMEA/H/C/005084/WS2469/0023
Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-

Berghaus

WS2472
Afinitor-
EMEA/H/C/001038/WS2472/0085
Votubia-
EMEA/H/C/002311/WS2472/0081
Novartis Europharm Limited, Lead Rapporteur:
Janet Koenig

WS2473
ProQuad-
EMEA/H/C/000622/WS2473/0161
Zostavax-
EMEA/H/C/000674/WS2473/0146
Merck Sharp & Dohme B.V., Lead Rapporteur:
Jan Mueller-Berghaus

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 23-26 April 2023 CHMP plenary:

Uro-nephrology	
Visual enhancement of the anatomic location of the ureters using near-infrared (NIR) fluorescent light (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Ophtalmology	
AGTC-501 (laruparetigene zovaparvovec) Treatment of XLRP ATMP	The CHMP granted eligibility to PRIME and adopted the critical summary report.

G.2.2. List of procedures starting in April 2023 for May 2023 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address